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Abstract 
 
Background: Understanding the development of resistance to treatments remains as 
one of the major challenges in melanoma therapy. It is well known that tumor cells 
undergo phenotype switching during melanoma progression, increasing plasticity and 
resistance to mitogen-activated protein kinase inhibitors (MAPKi). Therefore, studying 
melanoma phenotype switching could reveal new targets that could be used to 
overcome therapy resistance. Methods: A model of partial reprogramming was 
established to susceptibility of dedifferentiated melanoma cells to treatment with 
MAPKi in order to find new targets to overcome the resistance to MAPKi. Results: The 
results of this study show that partially reprogrammed C790 and 4434 cells were less 
proliferative, more invasive and more dedifferentiated cell population, expressing a 
gene signature associated with stemness and suppressing melanocyte-specific 
markers. To investigate the development of resistance to MAPKi, murine and human 
melanoma cells were exposed to BRAF and MEK inhibitors. Dedifferentiated cells were 
less sensitive to MAPKi, indicated by increased cell viability and decreased apoptosis. 
Furthermore, T-type calcium channels were overexpressed in partially reprogrammed 
C790 and 4434 cells, as well as in human adaptive resistant melanoma cells. 
Treatment with the calcium channel blocker mibefradil induced cell death, 
differentiation and susceptibility to MAPKi in vitro and in vivo in human adaptive 
resistant melanoma cells. Conclusions: The results of this study indicate that partial 
reprogramming represents an innovative model to study melanoma progression and 
the development of resistance to MAPKi. Moreover, the use of a calcium channel 
antagonist, such as mibefradil, enhances the effect of MAPKi, by restoring the 
sensitivity of resistant melanoma cells. 
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Zusammenfassung 
 
Hintergrund: Die Aufklärung der Mechanismen, die eine Entwicklung von 
Resistenzen gegen gängige Behandlungen bewirken, bleibt eine der größten 
Herausforderungen der Melanomtherapie. Es ist bekannt, dass Tumorzellen während 
der Melanomprogression einen phänotypischen Wechsel durchlaufen, welcher ihre 
Plastizität und auch die Resistenz gegen Mitogen-aktivierte Protein Kinase Inhibitoren 
(MAPKi) erhöht. Die Erforschung des Phänotypwechsels bei Melanomzellen könnte 
somit neue Angriffspunkte enthüllen, welche dazu genutzt werden könnten, um 
Resistenzmechanismen zu überwinden. Methoden: Ein Modell für partielle 
Reprogrammierung wurde entwickelt, um die Sensitivität von Melanomzellen mit 
unterschiedlichen Differenzierungszuständen gegenüber MAPKi-Behandlung zu 
untersuchen, um damit neue Ziele zur Überwindung von MAPKi-Resistenz zu finden. 
Ergebnisse: Die Ergebnisse dieser Untersuchung haben gezeigt, dass partiell 
reprogrammierte C790- und 4434-Zellen weniger proliferativ und invasiv sowie stärker 
dedifferenziert sind, als die parentalen Zellen. Sie weisen eine stammzellspezifische 
Gensignatur auf und exprimieren keine melanozytenspezifischen Marker mehr. Um die 
Resistenzentwicklung gegen MAPKi zu untersuchen, wurden murine und humane 
Melanomzellen BRAF- und MEK-Inhibitoren ausgesetzt. Dedifferenzierte Zellen waren 
weniger empfindlich gegenüber MAPKi, was sich in erhöhter Viabilität und verringerter 
Apoptose äußerte. Darüber hinaus wurden T-Typ Kalziumkanäle in partiell 
reprogrammierten C790- und 4434-Zellen sowie in humanen adaptiv resistenten 
Melanomzellen überexprimiert. Die Behandlung mit dem Kalziumkanalblocker 
Mibefradil induzierte in humanen adaptiv resistenten Melanomzellen den Zelltod, 
Differenzierung und die Empfindlichkeit gegenüber MAPKi in vitro und in vivo. Fazit: 
Die Ergebnisse dieser Untersuchung zeigen, dass partielle Reprogrammierung ein 
innovatives Model zur Untersuchung von Melanomprogression und 
Resistenzentwicklung gegen MAPKi darstellt. Darüber hinaus wird durch die 
Verwendung eines Kalziumkanal-Antagonisten wie Mibefradil die Wirkung von MAPKi 
verstärkt, indem die Empfindlichkeit von resistenten Melanomzellen wiederhergestellt 
wird. 
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1. Introduction 
 
Malignant melanoma is an aggressive type of skin cancer with survival rates and 
treatments that vary depending on tumor stages. While early stages have a good 
prognosis, unresectable stage III and IV melanomas are often fatal and therapy 
resistance is a major challenge. Around 50% of melanoma patients carry mutations in 
the BRAF gene and around 30% of patients in the NRAS gene resulting in an aberrant 
activation of the mitogen-activated protein kinase (MAPK) pathway1, making this 
signaling cascade one of the most important targets for melanoma therapy2,3.   
The clinical use of BRAF inhibitors (vemurafenib, dabrafenib, encorafenib), MEK 
inhibitors (trametinib, cobimetinib, binimetinib) or their combinations significantly 
increases progression-free (PFS) and overall survival (OS) of patients4. Unfortunately, 
most patients develop resistance to these inhibitors soon after the start of the therapy5,6 
because of different factors including tumor heterogeneity and plasticity7.  
The high cellular heterogeneity of melanomas is partially due to a degree of phenotypic 
plasticity. Melanoma cells switch between proliferative/differentiated and 
invasive/dedifferentiated phenotypes during metastasis progression, mimicking the 
epithelial-to-mesenchymal transition, which facilitates invasion to secondary tumor 
sites8–10. Indeed, induction of phenotype switching towards a dedifferentiated state is 
likely one of the most common mechanisms underlying the development of resistance 
to therapies in melanoma patients9. 
Drug resistance in melanoma has been classified as intrinsic, adaptive or acquired, 
depending on whether the resistance is present already before treatment or it develops 
either shortly or longer time upon beginning of treatment2,11. Several mechanisms have 
been reported to promote resistance in melanoma. These include reactivation of 
extracellular-signal regulated kinase (ERK) signaling or activation of alternative 
pathways2,5.In this study, partial reprogramming of melanoma cells was used12 to 
investigate the connection between de-differentiation and development of therapy 
resistance. 
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1.1 General aspects of melanoma 
1.1.1 Causes, incidence and Mortality 
Melanoma is a type of skin cancer that arises from melanin-producing cells called 
melanocytes.  The primary cause of melanoma is the ultraviolet (UV) radiation from 
the sun or other sources13, but also age, gender and family history are risk factors14,15. 
Melanoma not only emerges on skin exposed to sun but also from mucosa or skin that 
has not been exposed to sunlight. The incidence of melanoma has increased over the 
last decades and 132.000 new cases are reported each year worldwide. Additionally, 
it is estimated that 4.500 additional cases occur due to the decrease in ozone levels 
every year14,16,17. 
The classification of skin cancers includes non-melanoma skin cancers and 
melanoma. Non-melanoma skin cancers comprise basal cell carcinomas and 
squamous cells carcinomas. These carcinomas are frequent in body areas commonly 
exposed to sun, are rarely lethal, easy to treat, and their incidence increases with a 
decrease in latitude14. 
On the other hand, malignant melanoma is less frequent but is the main cause of 
deaths from skin cancers. The risk of developing melanoma correlates mainly with 
genetic characteristics, as well as UV exposure14,15. Caucasian populations have a 
higher risk of non-melanoma and melanoma skin cancers due to their reduced skin 
pigmentation. Persons with pale or freckled skin, red hair or blue eyes show the highest 
risk. However, regardless of these characteristics, excessive sun exposure can 
damage all types of skin15.  
Melanoma causes 9.000 deaths each year in the United States13 and is the fifth most 
common cancer in men and the seventh most common in women. Around the world, 
malignant melanoma is responsible for 75% of all deaths related to skin cancers15, and 
survival rates of melanoma patients highly depend on early detection and treatment. If 
melanoma is detected at an early stage, the prognosis is more favorable in comparison 
to melanoma that has already metastasized to other parts of the body14. 
 
1.1.2 Mutations  
As mentioned before, most of the melanoma cases are due to a certain degree 
(low/high) of exposure to UV radiation. UV light causes direct or indirect damage to 
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DNA of the cells and induce pyrimidine dimers (thymine or cytosine), which disturb the 
DNA structure and cause mutations during DNA replication or repair processes18,19. 
Mutations in proto-oncogenes (gain-of-function mutation) or tumor suppressor genes 
(loss-of-function mutations) alter their functions and initiate malignant transformation 
of normal cells19.  
One of the most common somatic mutation in melanoma occur in the B-raf proto-
oncogene serine/threonine kinase (BRAF), particularly the amino acid exchange 
V600E, where valine (V) at position 600 is substitute with glutamic acid (E). BRAF is 
critical for regulation of the MAPK signaling that promotes proliferation, differentiation 
and survival. BRAF mutations are found in approximately 60% of melanomas, from 
which V600E mutation represents 80%20 and promotes cancer progression by 
constitutively activating MAPK signaling (Figure 1). Mutations leading to different 
substitutions, such as V600K or V600R, are less frequent and represent only 20% and 
7% of the BRAF mutations, respectively20. Importantly, the BRAF V600E mutation is 
also present in 80% of non-malignant lesions (benign nevi), suggesting that BRAF 
mutations alone are not enough to drive carcinogenesis21.   
Among other somatic mutations that have been reported to promote melanoma 
progression are neurofibromin 1 (NF1), neuroblastoma rat sarcoma viral oncogene 
homolog (NRAS), tumor protein 53 (TP53), ras-related C3 botulinum toxin substrate 1 
(RAC1), phosphatase and tensin homolog (PTEN), tyrosine protein kinase kit (KIT), 
and cyclin-dependent kinase 4 (CDK4)21–23(Figure 1).   
NRAS belongs to the RAS family of G-regulatory proteins that regulate normal cell 
growth through the MAPK and PI3K/AKT/mTOR pathway. NRAS mutations at codons 
12,13 and 61 constitute the second most common driver mutations in melanoma (20%) 
and are associated with an increment in tumor aggressiveness and poor prognosis5,24. 
The RAS family also includes two more proto-oncogenes called Harvey Ras viral 
oncogene homolog (HRAS) and Kirsten Ras viral oncogene homolog (KRAS), but 
mutations in these genes are rare in melanomas21. 
Although melanomas often harbor several somatic mutations, also familial cases 
harboring a germline mutation in the cyclin-dependent kinase inhibitor 2A (CDKN2A) 
gene have been described in caucasian populations 25. CDKN2A is a tumor suppressor 
gene that encodes two proteins: p16INK4A and p14ARF, both proteins control the cell 
cycle progression. p16INK4A blocks the cyclin-dependent kinase 4 (CDK4)/Cyclin D1 
(CCND1) while p14ARF affects the murine-double-minute− 2 (MDM2) protein, 
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preventing the degradation of p5323,25. Therefore, CDKN2A mutations lead to 
uncontrolled cell-cycle progression, contributing to melanoma progression. The 
frequency of CDKN2A mutation is higher in malignant melanoma patients with a family 
history of melanoma compared to those without21,25.  
Finally, some melanomas also show mutations of the telomerase reverse transcriptase 
(TERT) promoter, increasing the expression of the enzyme telomerase. As a result, 
cells are able to evade senescence and keep undergoing cellular division, growing for 
long periods of time, which is known as cell immortalization21. Mutations in the TERT 
promoter region have been found in melanoma (29%) and in other types of cancer of 
the central nervous system (43%), the thyroid (10%) and the bladder (59%)26. 
Over the last years, new significant mutations have been discovered in melanomas 
affecting a plethora of genes: AIRD2, PPP6C, SNX31, TACC1, STK19 MAP2K1, IDH1, 
RB1 and DDX3X22,23,27. The identification of important mutations in melanoma has 
improved the efficacy of treatments by increasing survival rates in patients. 
Considering the variety of the genes that are mutated in melanoma, knowing the 
mutational status of melanoma patients is indeed essential for an appropriate selection 
of a therapy.  
 
 
 
Figure 1. The most frequent genetic alterations during melanoma progression. Initial 
malignant transformation of melanocytes is driven by mutations on BRAF and NRAS. 
However, accumulation of additional mutations must occur to support the tumorigenesis (e.g. 
CDK4, NF1, TP53, PTEN, CDKN2A). Adapted from Vultur & Herlyn 2013, Cancer Cell 28.  
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1.1.3 Deregulated pathways  
Under physiological conditions, cell proliferation is tightly controlled and closely 
connected with apoptosis in order to maintain an appropriated number of healthy cells, 
eliminate unwanted or damaged cells and with this assure tissue homeostasis. 
Alterations in either one of these processes usually lead to uncontrolled growth and 
tumor formation29. 
The MAPK and PI3K/AKT/mTOR pathways regulate cell proliferation, survival, 
migration, differentiation and metabolism. In cancer, these pathways are constitutively 
activated and both cascades can interact to promote growth and survival of malignant 
cells30,31.  
MAPK pathway is activated by growth factors, hormones, chemokines and other 
molecules, which bind to catalytic receptors like receptor tyrosine kinase (RTK), G 
protein-coupled receptors, or direct activation of protein kinase C30. MAPK signaling 
initiates with activation of the Ras-family GTPases. Once active, GTP-bound Ras 
activates a cascade of serine/threonine protein kinases starting with the protein kinase 
RAF (MAPKKK), which has three isoforms: ARAF, BRAF and CRAF. RAF is 
responsible for the phosphorylation and activation of the protein kinase MEK1 and 
MEK2 (MAPKK) which in turn phosphorylate and activate the effector protein kinases 
ERK1 and ERK2 (MAPK)29,31 (Figure 2).  
ERK constitutes the main protein kinase in this pathway due to its final cellular 
functions. Activated ERK can phosphorylate cytoplasmic proteins like the ribosomal 
S6 kinase (RSK), or translocate to the nucleus and phosphorylate transcription factors 
including the ternary complex factor (TCF) which induce expression of immediate early 
genes (IEG). The IEG products (c-MYC, c-Fos) induce expression of late-response 
genes that promote cell division, motility and cell survival29–31.  
Melanoma like other types of cancer arises from accumulation of mutations that 
constitutively activate pro-proliferative and pro-survival pathways30. Most of the 
patients carrying BRAF mutations show an over-activation of MAPK signaling, making 
this pathway one of the most important targets for melanoma therapy. Mutations in 
components of the PI3K/AKT/mTOR pathway and the tumor suppressor gene PTEN 
in melanoma have also been reported, but at a lower frequency5 (Figure 2).  
The PI3K/AKT/mTOR pathway is also activated by growth factors that bind to catalytic 
receptors RTK or can be induced by GTP-bound RAS protein. RTK activation recruits 
the phosphatidylinositol 3-Kinase (PI3K) heterodimer to the plasma membrane. PI3K 
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belongs to a family of lipid kinases that phosphorylate specific substrates. PI3K 
phosphorylates the substrate PIP2 to produce PIP3. Importantly, PTEN promotes 
dephosphorylation of PIP3 to PIP2, negatively regulating the PI3K/AKT/mTOR 
pathway.  
PIP3 recruits and activates proteins with pleckstrin homology (PH) domains, among the 
proteins containing PH domains are the AKT and 3-phosphoinositide-dependent 
kinase 1 (PDK1). AKT kinase is recruited to the plasma membrane by PIP3 and then 
activated by PDK1. Once active, AKT can phosphorylate different proteins to activate 
(mTOR, NFkB, MDM2) or inactivate (IKKα or pro-apoptotic proteins) them, in order to 
promote cellular survival29,30. 
There is evidence that the MAPK and PI3K/AKT/mTOR pathways are interconnected 
by different mechanisms of cross-activation, cross-inhibition and convergence31. For 
instance, ERK can inactivate mTOR complex 1 and 2 by dissociation of their dimers, 
impairing the role of mTOR complex 2 to inhibit mTOR signaling30. Inhibition of one of 
these pathways often leads to the activation of the other signaling cascade, therefore, 
blockage of both pathways is considered as a good strategy to eliminate cancer cells29. 
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Figure 2. Most common deregulated pathways in melanoma. Extracellular signals like 
growth factors can lead to activation of MAPK and PI3K/AKT/mTOR pathways through 
membrane receptors RTK. RTK phosphorylate Ras protein, which initiates the activation of the 
cascade of kinases RAF, MEK and ERK. Ras protein can also activate PI3K that transforms 
PIP2 to PIP3, activating AKT kinase. AKT has several targets like mTOR, MDM2 and NFkB. 
Activation of these pathways induces transcription of specific genes that increase cell 
proliferation and survival. Adapted from Vultur & Herlyn 2013, Cancer Cell 28.  
 
1.1.4 Phenotype switching  
Melanoma is a tumor with high heterogeneity that shows phenotypic plasticity as a 
consequence of genetic mutations, micro environmental signals, and reversible 
epigenetic changes32. Melanoma cells can switch between proliferative/differentiated 
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and invasive/dedifferentiated phenotypes during metastasis progression, in a similar 
way to epithelial-to-mesenchymal transition (EMT), which facilitates dissemination 
from a primary tumor to distant sites through the transition into an invasive phenotype8–
10. Besides cell-intrinsic proliferation and migration factors, tumor micro environmental 
conditions such as hypoxia32–34 and inflammatory signals can also promote melanoma 
phenotype switching (Figure 3). 
In order to induce the switch between proliferative and invasive phenotypes different 
cellular events must occur. For instance, invasive capacity of BRAF mutant melanoma 
cells has been associated with a switch in expression of cadherin proteins35. During 
metastasis, there is a progressive loss of E-cadherin and an increase in levels of N-
cadherin. This switch from E-cadherin to N-cadherin promotes survival and migration 
of melanoma cells9,32,35. In addition, Bettum and collaborators (2015) demonstrated 
that the transformation into the invasive phenotype in melanoma facilitates de-
differentiation and a metabolic switch from mitochondrial oxidation to glycolysis, which 
is beneficial for survival and growth of cancer cells during phenotypic transition. 
Regardless, the central factor involved in melanoma phenotype switching is the 
microphthalmia-associated transcription factor (MITF), which regulates the expression 
of melanocyte differentiation and pigmentation genes and is responsible for reversible 
and functional reprogramming of signaling pathways in melanoma36,37. MITF is a 
lineage-specific oncogene highly expressed in human melanomas that contributes to 
tumorigenesis38,39. 
Goding and collaborators (2011) proposed that the level of MITF activity correlates to 
the phenotype switching in melanoma tumor cells. According to the “MITF rheostat” 
model, a high level of MITF activity promotes differentiation, mid-level activity promotes 
proliferation, and  low-level activity promotes an invasive, stem cell-like phenotype, and 
the absence of MITF activity causes senescence or cell death40 (Figure 3). 
Moreover, reduction of MITF expression in melanoma cells has been related to 
increased plasticity and therapy resistance, supporting that induction of phenotypic 
switching toward a more dedifferentiated state drastically determines the 
aggressiveness of the tumor and constitutes an important mechanism underlying the 
development of resistance to therapies in melanoma patients41–43.  
In addition, expression of MITF and other genes involved in phenotype switching and 
metastasis permits to discriminate between BRAFi-sensitive and BRAFi-resistant 
melanoma cells, based on their RNA expression signatures. Sensitive melanoma cells 
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show high activity of MITF and downstream differentiation markers including 
tyrosinase-related protein1 (TYRP1), melan-A (MLANA) and pre-melanosomal protein 
(PMEL), whereas resistant cells show low MITF activity but high expression of NFkB, 
Wnt5 and the receptor tyrosine kinase AXL36,39,44. Furthermore, expression of MITF 
and AXL has been reported in several melanoma cells and the ratio MITF/AXL has 
been used to describe early resistance in melanoma44.  
 
 
 
Figure 3. Characteristics of phenotype switching in melanoma. There are several factors 
that promote phenotype switching, including hypoxia, growth factors, epigenetic changes, and 
others. Melanoma cells can switch between a proliferative and an invasive phenotype, inducing 
a more dedifferentiated status and poor response to treatments. MITF is the main factor that 
drives melanoma phenotype switching and its expression correlates with each specific 
phenotype and the therapy response. Adapted from Vandame & Berx 2014, Frontiers in 
Oncology 8.  
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1.2 Treatments for melanoma 
1.2.1 Surgery and chemotherapy 
Current therapeutic options for melanoma patients involve surgical excision, 
chemotherapy, immunotherapy and targeted therapy (Figure 4). Generally, surgery is 
one of the first options for patients at early and intermediate-stages of the disease, with 
high rate of success. However, for patients in stage IV, the main option of treatment 
consists of systemic therapies including chemotherapy, immunotherapy or 
combinatorial approaches. Although melanoma is considered to be relatively 
radioresistant to radiotherapy, it is frequently used for the treatment of patients with 
metastases in the central nervous system (CNS) due to limited penetration of systemic 
drugs into the CNS45.  
Regardless of all the latest advances in treatment options, chemotherapy together with 
high dose interleukin-2 (IL-2) has been extensively used for the treatment of advanced 
stages of melanoma for several decades. Although chemotherapy is no longer a 
frontline therapy in advanced-stage melanoma, it still is a suitable treatment for 
melanomas that do not show somatic mutations that can be targeted with specific 
inhibitors. In these cases, usually after receiving immunotherapy, the next line of 
treatment is chemotherapy46 (Figure 4).  
Several chemotherapeutic agents have been used as single-agent chemotherapy or 
in combination for the treatment of advanced melanoma, including dacarbazine, 
temozolomide, nitrosoureas (carmustine and lomustine), carboplatin, cisplatin and 
taxanes (paclitaxel and docetaxel)46.    
Dacarbazine is an alkylating agent that forms DNA adducts, inducing DNA damage 
and cytotoxic effects in the cells45. Dacarbazine was approved by the FDA in 1975 for 
melanoma treatment and since then is considered the standard chemotherapy for 
patients with metastatic melanoma. Doses and side effects (nausea and vomiting) of 
dacarbazine vary but it is tolerated quite well in general.  
Another alkylating agent used for treatment of advanced melanoma is temozolomide, 
an analog of dacarbazine that is also approved for glioblastoma treatment. 
Temozolomide is administered orally and can cross the blood-brain barrier thus 
causing headache, nausea and vomiting as main side effects45. Studies have shown 
no differences in the efficacy of temozolomide and dacarbazine, bringing the possibility 
of using both agents interchangeably46. Nitrosoureas are also alkylating agents that 
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have been used in combination, in most of the cases, for the treatment of advanced 
melanoma.  
The platinum analogs cisplatin and carboplatin are used against several solid tumors. 
Patients with metastatic melanoma treated with carboplatin have shown a positive but 
more moderate effect compared to dacarbazine47. Finally, taxanes are 
antimicrotubular agents that affect tubulin polymerization and microtubule formation, 
resulting in dysfunctional mitotic spindle complexes and cell death. Paclitaxel 
specifically inhibits the microtubule disassembly and has shown a modest effect as 
single or in combinatorial treatment in patients with metastatic melanoma, while 
docetaxel has shown a more potent outcome. Combination of platinum analogs and 
taxanes have also been tested for treating of advanced stages of melanoma with 
positive results46,47.  
Additional combinations of chemotherapy along with immunotherapy have been 
evaluated (biochemotherapy). For instance, combination with interferon alpha (INF-α) 
and IL-2 have been extensively tested on advanced-stage melanoma patients with 
response rates between 10-20 % and 15-20 %, respectively. However, severe toxicity 
is usually observed in this biochemotherapy regimen and the results are not translated 
into an OS benefit. Therefore, this approach is not considered anymore as a standard 
treatment for patients with advanced melanoma46. 
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Figure 4. Current systemic treatments approved for patients with unresectable 
metastatic melanoma. First line of treatment varies depending on the mutation status of the 
patient and how fast the disease progresses. Patients with BRAF-mutant melanoma receive 
targeted therapies or immunotherapies as first line of treatment, because immunotherapy may 
take longer, BRAFi monotherapy or the combination with MEKi is preferred. If there is no 
response, patients then can receive immunotherapies as second line of treatment. Patients 
with BRAF-wild type tumors receive immunotherapies as first line of treatment. Moreover, 
chemotherapy is also administered as a second line of treatments and some cases can be 
treated locally using oncolytic virus-based therapy. Adapted from Kozar et al 2019, Reviews 
on Cancer 48.  
 
1.2.2 Targeted therapy 
Targeted therapy specifically eliminates cancer cells that harbor targets that are 
exclusively expressed by these cells. Since BRAF mutations were described as the 
most frequent mutations in melanoma, development of BRAF inhibitors (BRAFi) and 
MAPK inhibitors (MAPKi) has increased (Figure 5).  
Inhibitors of RAF protein include type I inhibitors that selectively inhibit the activated 
RAF kinase, like vemurafenib and dabrafenib, and the type II inhibitors, which inhibit 
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the resting RAF protein, like sorafenib. Although melanoma cells carrying BRAF 
mutations are sensitive to both types of inhibitors, type I inhibitors have demonstrated 
better results compared to type II inhibitors in the treatment of BRAF-mutant metastatic 
melanoma 46.  
During initial trials in 2010, targeted therapy generated significant results in several 
patients with metastatic melanoma, producing a partial or complete tumor regression. 
Vemurafenib was the first FDA-approved BRAF V600E inhibitor and improved OS (6 
months survival rate, 84% vs 64%) and PFS (5.3 vs 1.6 months) compared to the 
traditional chemotherapy with dacarbazine49. Unfortunately, long-term follow-up 
studies reported limited OS up to 16 months among patients treated with vemurafenib 
monotherapy. 
Importantly, not all BRAF-mutant patients respond to inhibition with vemurafenib or 
dabrafenib and usually resistance to these monotherapies appears in most patients, a 
few months later46. In addition, treatment of melanoma cells with wild-type BRAF with 
RAF inhibitors leads to a paradoxical increase of the MAPK pathway and ERK activity. 
This because the inhibition of BRAF in these wild type BRAF cells enhances signaling 
through CRAF and as a result the pathway remains activated50.  
Due to the constant MAPK pathway activation, even after development of resistance 
to BRAF inhibitors, several clinical trials have evaluated MEKi alone or in combination 
with type I RAF inhibitors. MEK inhibitors inhibits the kinases MEK1 and MEK2 of the 
MAPK pathway and have been used for treatment in some cancers, especially BRAF-
mutant melanoma51 (Figure 5). 
In 2013, the FDA approved the use of trametinib for the treatment of BRAF-mutant 
melanoma, after results of clinical trials that evaluated the efficacy of trametinib 
monotherapy showed a significantly increased 6-month OS rate (81% vs 61%) 
compared to chemotherapy51. 
Moreover, the combination of BRAFi (dabrafenib) and MEKi (trametinib) for treating 
BRAF-mutant metastatic melanoma has shown an improvement of PFS (9.4 vs 4.8 
months), OS and the rate of partial or complete response (76% vs 54%) compared to 
dabrafenib monotherapy52. In addition, combination of vemurafenib with the MEKi 
cobimetinib significantly increased the PFS compared to vemurafenib monotherapy 
plus placebo (9.9 vs 6.2 months)53,54.  
Furthermore, preclinical studies on NRAS-mutant melanomas demonstrated that these 
tumors are relatively insensitive to vemurafenib treatment. However, according to a 
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phase II study that reported 20% of partial response, the treatment with MEKi 
binimetinib may be effective against NRAS-mutant melanomas. Additionally, new MEK 
inhibitors are under clinical investigation as single treatments or in combination, 
including TAK733 and selumetinib for advanced metastatic melanoma46. 
Finally, as mentioned before, PIK3/AKT/mTOR signaling is an important pathway that 
drives tumorigenesis and resistance in melanoma. Preclinical studies have reported 
the utility of inhibition of PIK3/AKT/mTOR in melanomas with resistance to 
vemurafenib and dabrafenib55,56. However, clinical trials using combination of these 
inhibitors are still ongoing and involve c-Kit inhibitors (sunitinib, imatinib, dasatinib) and 
mTOR inhibitors (temsirolimus and everolimus)57  (Figure 5). 
 
 
Figure 5. Therapeutic targets in the MAPK and PI3K/AKT/mTOR cascades developed for 
targeted therapy of melanoma. Several inhibitors have been developed to inhibit the main 
pathways aberrantly activated in melanoma. BRAF, MEK, mTOR and RTKs are the main 
therapeutic targets for melanoma treatment. Adapted from Tran et al 2016, Drug design, 
Development and Therapy58 . 
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1.2.2 Immune checkpoints inhibitors  
Long-term survival rates for patients with metastatic melanoma are a very low 
percentage but, with the latest advances in treatments with immune checkpoints 
inhibition and targeted therapy, the clinical outcome of the patients has improved.  
Tumor cells can escape immune recognition and elimination by selection of clones 
able to evade the immune system (immunoediting), by downregulating factors that 
make them vulnerable such as tumor antigens or MHC class I or by activating negative 
feedback mechanisms that prevent immunopathology. These mechanisms include the 
secretion of inhibitory cytokines (IL-10), recruiting inhibitory cell types (T-regs, B-regs 
and MDSC), and producing metabolic modulators (IDO) and inhibitory receptors like 
PD1 and CTLA-4, also known as immune checkpoint molecules59.  
The FDA-approved immunotherapies for the treatment of metastatic melanomas 
including the cytotoxic T lymphocyte-associated antigen (CTLA-4) antibody called 
ipilimumab, and the programmed cell death 1 (PD-1) receptor antibodies called 
nivolumab or pembrolizumab. These three immune checkpoint inhibitors have been 
used as first or second line of treatment for advanced melanomas, as single treatment 
or in combination (nivolumab + ipilimumab) with promising results60 (Figure 4). 
CTLA-4 belongs to the B7/CD28 family and is constitutively expressed on regulatory T 
cells, contributing to their inhibitory functions. CLTA-4 is also expressed on T 
lymphocytes upon activation and acts like a negative regulator of T-cell activation. 
CTLA-4 counteracts positive stimulatory signals by binding to B7-1 and B7-2 receptors 
and competing with CD28, a co-stimulatory molecule59. Due to the inhibitory role of 
CTLA-4 during T-cell activation, Leach and collaborators (1996) tested the hypothesis 
that blockage of CTLA-4 could increase immune response against tumor cells. The 
study showed a rejection of tumor after CTLA-4 administration in vivo, supporting that 
blockage of inhibitory functions of CTLA-4 enhances anti-tumor immune response61.  
CLTA-4 was the first FDA-approved immune checkpoint inhibitor for the treatment of 
cancer patients. Clinical trials on patients with advanced melanoma patients reported 
an improvement of OS using ipilimumab (10 months) compared to peptide vaccines 
(6.4 months)62. Moreover, treatment with ipilimumab alone compared to dacarbazine 
showed an increment in survival (47.3% vs 36.3%) after 1 year of initial treatment63.  
Strategies that block other immune checkpoint molecules have also demonstrated 
positive results in melanoma patients. This was the case for the anti-PD 1 drugs 
nivolumab and pembrolizumab. PD-1 negatively regulates T-cell activity by interacting 
 34 
with its ligands PD-L1 and PD-L2. Once PD-1/PD-L1 pathway is activated, PD-1 
inhibits the kinase cascade responsible for T cell activation. PD-L1 is also expressed 
on regulatory T cells, enhancing their immunosuppressive functions as well59,64.  
Phase I studies on patients with advanced melanoma have shown long response rates 
(40%) with minimal toxicity after treatment with nivolumab65. Other studies have 
demonstrated a higher response rate for nivolumab compared to dacarbazine66. 
Pembrolizumab also have showed similar efficacy to nivolumab with regard to tumor 
responses. More importantly, pembrolizumab was approved to be used in patients 
previously treated with ipilimumab or BRAF inhibitors67. Some of these studies are 
currently under process.   
In the case of immunotherapy using antibodies against PD-L1, this seems to be a 
promising approach but clinical studies are still ongoing. PD-L1 also inhibits T cell 
activity by binding to B7 ligand. However, targeting PD-L1 may result in a different 
immune response than targeting PD-1 46. Antibodies that block PD-L1 do not prevent 
PD-1 from interacting with PD-L2.   
 
1.2.3 Other treatments 
Considering the latest scientific advances in therapeutic strategies for advanced 
melanoma, patients now have access to more effective and personalized therapies. 
Among these therapies are adoptive cell therapy (ACT), CAR modified T cells, and 
oncolytic viral therapy.  
ACT involves the collection of lymphocytes from patients, either peripheral or tumor-
infiltrating lymphocytes (TILs), then selection, expansion and activation in vitro, 
followed by transfusion of the processed lymphocytes back into the patient to induce a 
specific immune response against cancer cells45. Several studies have evaluated 
efficacy of adoptive T-cell transfer. Hunder and collaborators (2008) showed that 
isolation and expansion of autologous CD4+ T cells with specificity for the melanoma-
associated antigen NY-ESO-1 successfully induced a durable anti-tumor response in 
patients with refractory metastatic melanoma, after CD4+ T cells were transfused back 
into the patient68. 
Furthermore, by using gene therapy to introduce TCRs or chimeric antigen receptors 
(CARs), T cells that target any antigen of interest can be generate. The CAR receptors 
combine a high-affinity antigen recognition domain with the efficient killing machinery 
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of T cells. This is possible by creating a molecule that links the variable domains of an 
antibody to the intracellular signaling domains of the TCR complex, in this way, the 
recognition by CARs is HLA-independent and is directed to a specific protein 
expressed on tumor cells46. Because initial studies did not show the expected results, 
for the next generations of CARs, intracellular domains of costimulatory molecules 
(CD27, CD28, CD19) were added, improving the clinical benefit especially in 
leukemias69. Currently, second and third generation of CAR T cells are the most 
effective effector T cells in use, however, their efficacy is limited to hematological 
malignancies than solid tumors. Preclinical studies with CAR T cells in melanoma are 
still under investigation70.  
On the other hand, oncolytic viral therapy using the genetically modified virus talimogen 
laherparepvec (T-VEC) has shown promising results for melanoma treatment (Figure 
4). T-VEC can target tumor cells and induce anti-tumor immune response. T-VEC 
carries the gene for granulocyte macrophage colony-stimulating factor (GM-CSF) and 
has tumor selectivity64,71. A phase III study showed clinical benefits and durable 
response in patients with unresectable melanoma in comparison to patients treated 
with subcutaneous injections of GM-CSF 72.  
 
1.3 Resistance to targeted therapy in melanoma 
1.3.1 Types of resistances 
Regardless the great variety of therapeutic options for the treatment of metastatic 
melanoma, the efficacy of treatments remains unsatisfactory due to the development 
of resistance followed by recurrence of the disease.   
With the discovery and initial administration of the combination therapy with BRAF and 
MEK inhibitors, the PFS and OS improved in metastatic melanoma patients. About 
90% of the patients showed some improvement or tumor regression, achieving partial 
or complete responses. These responses although promising were limited, with only 
few long-term and durable responses49. Unfortunately, about 50% of patients that show 
initial improvement, usually relapse within 7 months of treatment, a condition referred 
to as acquired resistance. Moreover, there are approximately 10% of patients that do 
not respond to targeted inhibition at all, showing an intrinsic or primary resistance to 
targeted therapy73.  
 36 
Hence, resistance to BRAF inhibitors can be caused by the presence of mutations in 
melanoma cells before start of the treatment (intrinsic resistance) or by the acquisition 
of new mutations in melanoma cells upon treatment (acquired resistance) (Figure 6). 
Recently, different studies have reported a type of adaptive resistance in melanoma 
cells74–76 that involves initial cellular adjustments that allow melanoma cells to adapt, 
proliferate and survive shortly after starting the treatment. This mechanism of 
resistance may underlie the development of acquired resistance by providing time to 
melanoma cells to develop additional mutations76.  
 
1.3.2 Mechanisms of resistance to BRAF inhibitors 
Among the mechanisms driving intrinsic or primary resistance are: amplification and 
overexpression of cyclin D1, RAC1 and HOXD8, alterations in the PTEN tumor 
suppressor gene, loss of NF1, microenvironmental factors like secretion of hepatocyte 
growth factor (HGF) by stromal cells with the subsequent activation of c-Met receptor, 
and reactivation of MAPK and PI3K/AKT/mTOR signaling2,5 (Figure 6). 
Moreover, reactivation of MAPK pathway is the most frequent cause of acquired or 
secondary resistance to BRAF and MEK inhibitors and can be divided into two main 
groups: MAPK-dependent and MAPK-independent mechanisms2 (Figure 6). MAPK-
independent mechanisms include activation of alternative pathways like 
PI3K/AKT/mTOR signaling, loss of PTEN and amplification of AKT protein, whereas 
MAPK-dependent mechanisms involve alternative splicing or amplification of BRAF, 
NRAS mutations, mutations in the kinase MEK1/2, overexpression of COT, alterations 
in MITF expression, upregulation of RTKs and reactivation of ERK2,5,77 (Figure 7).  
Together, these mechanisms provide melanoma cells with a survival advantage 
towards BRAF and MEK inhibitors treatment, by enhancing proliferative pathways and 
inhibiting cell death.  
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Figure 6. Mechanisms associated with the different types of resistance to BRAF 
inhibitors in melanoma. Intrinsic resistance is driven mainly by pre-existing mutations before 
the start of the treatment. Acquired resistance develops after approximately 6-8 months and 
involves either mechanisms associated with ERK reactivation or alternative pathways 
independent of MAPK reactivation. Adapted from Muñoz-Consuelo et al 2015, Ann Transl 
Med2. 
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Figure 7. Mechanisms associated with acquired resistance to BRAF inhibitors in 
melanoma. The mechanisms behind acquired resistance are divided into MAPK-dependent 
and MAPK-independent mechanisms. However, the main cause of acquired resistance is the 
reactivation of MAPK pathway. Adapted from Muñoz-Consuelo et al 2015 and Manzano et al 
2016, Ann Transl Med2,5. 
 
Unlike acquired resistance, the mechanisms driving adaptive resistance to BRAF 
inhibitors are rapid responses that occur just a few hours upon treatment. Drug 
withdrawal can reset the compensatory mechanisms during the adaptive response that 
usually involve an increase in pro-survival pathways, stablishing the preliminary set up 
for the acquired resistance76,78.  
Adaptive resistance mechanism can be subdivided into three groups: re-setting 
ERK1/2 protein, overexpression of RTKs with activation of PIK3/AKT/mTOR, and 
changes in metabolic pathways. Re-setting of ERK signaling has been reported in 
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some BRAF mutant melanoma cells after treatment with BRAFi, mainly due to a 
reduction of negative feedback regulators79.  
Among all the RTKs involved in resistance, the v-erb-b2 avian erythroblastic leukemia 
viral oncogene homolog 3 (ERBB3) receptor and the platelet derived growth factor 
receptor (PDGFR) are both upregulated during adaptive response to BRAFi76. ERBB3 
is a member of the epidermal growth factor family of RTKs and exhibits low kinase 
activity in comparison with other members. Abel and collaborators (2013) reported and 
upregulation of ERBB3 just a few hours after treatment with vemurafenib in melanoma 
cells that depends on FOXD3 activity. This effect was reversible upon drug removal80.  
Although differences between adaptive and acquired resistance mechanisms seem 
minor, identification of early factors involved in adaptive response to BRAF inhibitors 
is essential to develop combinatorial treatments that enhance current efficacy of target 
therapies in metastatic melanoma. 
 
1.4 Cellular reprogramming  
1.4.1 De-differentiation, reprogramming and transdifferentiation 
According to Waddington’s epigenetic landscape model, cells develop from a 
progenitor stem cell to a mature, fully differentiated and functional cell. In this model, 
cells are depicted as balls rolling down through the epigenetic landscape and falling 
into deeper valleys that determinate their fate during normal cell development and 
maintenance81. Although this process was thought to be unidirectional, research on 
different cellular phenomena such as dedifferentiation, transdifferentiation and 
reprogramming has shown that the process can be reversed82 (Figure 8).  
The term dedifferentiation describes the conversion of a fully differentiated cell into a 
more primitive and less differentiated cell type. The complete dedifferentiation towards 
a pluripotent stage is called reprogramming, while transdifferentiation refers to the 
conversion of one differentiated cell type into another83. Although the terms de-
differentiation and reprogramming are usually used interchangeably, reprogramming 
implies completed dedifferentiation into a pluripotent state, while dedifferentiation itself 
does not necessarily end in pluripotency but involves intermediated stages that are 
reversible83. 
Cancer progression resembles the process of cellular reprogramming. Transformed 
cells can display features of pluripotent-like cells losing their original cell identity and 
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expressing transcription factors that are commonly expressed in embryonic stem cells 
(ESC)84,85. Therefore, molecular mechanisms responsible for cell fate maintenance 
and self-renewal of progenitor cells might also be involved in the development and 
progression of cancer. 
Tumor cells that show self-renewal capacity and that give rise to heterogeneous 
progeny of cancer cells within the tumor are defined as cancer stem cells (CSC), a 
unique subpopulation of cells that can self-replicate indefinitely and is insensitive to 
anticancer therapies84. 
The CSC model suggests that the CSCs maintain the malignant growth through their 
ability to self-renew and their capacity to give rise to a progeny with limited proliferative 
capacity. This suggest a hierarchy where CSC are responsible to generate all the 
different types of cells within a tumor and increasing tumor heterogeneity84. Several 
studies have shown that this hierarchical CSC model can be bidirectional in some 
tumors, reporting that non-CSC dedifferentiate and acquire CSC-like features under 
certain conditions, causing tumor cell plasticity85,86(Figure 8).  
A better understanding of the changes that occur during cellular reprogramming might 
provide new insights into cancer initiation, progression and recurrence. The 
development of alternative models to study cancer plasticity and generation of CSC is 
essential to improve the efficacy of current cancer treatments and escape therapy 
resistance.  
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Figure 8. Comparison between normal development and cancer, using a representation 
of the epigenetic landscape described by Waddington. Pluripotent cells can differentiate 
into cells from different lineages. The opposite process is known as reprogramming, where 
pluripotency state is induced. Additionally, differentiated cells can switch between lineages, a 
process known as transdifferentiation. In cancer, cancer stem cells can generate differentiated 
and transformed cells within the tumor, increasing the tumor heterogeneity and prolonging 
tumor growth. Adapted from Waddington, C.H. (1957). The Strategy of the Genes81. 
 
1.4.2 Stem cells and iPSCs  
Stem cells are undifferentiated cells that can self-renew and that have the potency to 
differentiate into different specialized cell types. Based on their differentiation potential, 
stem cells can be classified as totipotent, pluripotent, multipotent or unipotent 87,88. 
Totipotent cells are the only cells able to produce a fertile adult individual. The zygote 
and early blastomeres are totipotent.  
Pluripotent cells include ESCs, perinatal stem cells, and induced pluripotent stem cells 
(iPSCs). ESCs can be isolated from the inner cell mass of the blastocyst and can give 
rise to every cell type from the three embryonic germ layers (ectoderm, mesoderm and 
endoderm), but not the extraembryonic tissue like placenta and umbilical cordon89. 
Indeed, ESCs and iPSCs both can form teratomas, encapsulated tumors consisting of 
different differentiated cells from all three embryonic germ layers. 
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iPSCs share many properties with ESCs and have been derived from many types of 
somatic cells by a process called cellular reprogramming. In order to produce iPSCs, 
either the genome, the environment or both have to be manipulated to successfully 
reprogram somatic cells.  
As mentioned earlier, reprogramming is a cellular process in which a fully differentiated 
cell reverts to a pluripotent state with the potential to differentiate into all cell types of 
the three germ layers. The concept of cellular reprogramming was first investigated by 
John Gurdon in 1958, when he and his collaborators successfully transferred a nucleus 
from an embryonic cell into an enucleated and unfertilized egg and thereby initiating 
nuclear reprogramming of a differentiated cell90.  
Later, iPSCs were successfully generated by direct reprogramming using a 
combination of only four transcription factors: Oct4, Sox2, Klf4 and c-Myc (OSKM)91 
that were ectopically expressed in somatic cells. Since then, different combinations of 
transcription factors including Nanog or Lin28 have been utilized to successfully 
produce iPSCs in vitro and in vivo from somatic cells in different organisms92–94. Other 
strategies for reprogramming involve cell fusion, transfection with miRNAs, and even 
the use of small molecules that can enhance reprogramming of somatic cells, including 
vitamin C, valproic acid (histone deacetylase inhibitor) or 5-azacytidine (DNA 
methyltransferase inhibitor)95,96. 
Although reprogramming seems a stochastic process at the beginning, where genes 
are repressed or activated apparently without a specific pattern, it is well known that 
there are specific genetic programs that must unlock as well as particular epigenetic 
changes that must occur (DNA methylation and histone modifications) to facilitate 
reprogramming97. During the initial phase of reprogramming, transcription factors Oct4, 
Sox2, Klf4 but not c-Myc, can access chromatin at distal elements and activate silent 
genes such as ESRRB and Sall4 that are required to induce pluripotency. Particularly, 
Oct4 has an essential role during reprogramming by binding to the enhancer elements 
of the Nanog, POU5F1 and MYOD1 genes. Moreover, c-Myc can co-bind to OSK at 
the distal elements, which promotes open chromatin and access to promoters, 
resulting in amplification of gene expression98. 
Later, induction of ectopic expression of c-Myc leads to an increase in proliferation 
through upregulation of several pathways. At the same time, transcription factors can 
induce metabolic switch from oxidative phosphorylation to glycolysis, which enhances 
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the efficiency of cellular reprogramming. These features are commonly seen in 
pluripotent cells, adult stem cells and cancer cells99,100.  
For successful reprogramming, active expression of endogenous stemness related 
genes like Oct4, Nanog and Sox2 is indispensable to maintain pluripotency 
independently of the expression of exogenous transcription factors. Oct4 and Nanog 
are key regulators of reprogramming in cooperation with Sox2 due to their role in 
embryogenesis101. Studies show that these three transcription factors bind to 
pluripotency-specific genes forming a regulatory loop that maintains their own 
expression as well as the expression of other key genes. Moreover, a complete 
repression of lineage-specifying genes is necessary to activate self-renewal and other 
properties of pluripotent cells101. 
In contrast to pluripotent stem cells, somatic or adult stem cells are tissue-restricted 
and can only differentiated into a few cell types within one particular lineage 
(multipotent) or into only one type (unipotent) depending on their differentiation 
potential. In general, adult stem cells can regenerate the cell types from the specific 
tissue or organ where they reside87–89. For instance, hematopoietic stem cells in the 
bone marrow can generate all types of red blood cells, white blood cells and platelets 
but not liver or brain cells.   
 
1.4.3 Cellular reprogramming and cancer  
Due to all the genetic and epigenetic alterations that occur during the process of de-
differentiation, one of the numerous applications for cellular reprogramming is disease 
modeling, including cancer. De-differentiation has been established as a hallmark of 
cancer progression and contributes to the acquisition of plasticity and therapy 
resistance in tumor cells43,86. Different studies have reported that poorly differentiated 
tumors possess an embryonic stem-like gene signature, expressing different stem cell-
related factors like Oct4, Nanog and Sox285,86. 
Typically, cellular reprogramming is associated with tissue regeneration102–104. 
However, this process has also been related to cancer initiation, progression and 
recurrence. Certainly, reprogramming of cancer cells can explain the phenotypic and 
functional heterogeneity observed among cancer cells105.  
Cancer cell subpopulations are organized in a hierarchical fashion, with the CSCs at 
the top. CSCs display stemness features, tumor initiation capacity in several types of 
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cancer, and are usually quiescent which allows them to survive the toxic effects of 
many anti-cancer treatments105. Somatic stem cells and CSCs use common regulatory 
mechanisms including Notch, Wnt and Hedgehog pathways, as well as stemness-
related transcription factors. Indeed, each of the transcription factors used for cellular 
reprogramming also plays a role in tumorigenesis, including Oct4, Sox2, Nanog, Klf4 
and Lin2884,85.  
Based on the theory that CSCs arise from normal stem cells or from a specific 
population of progenitor cells with self-renewal and unlimited proliferation capacity, 
many cancers might originate from somatic stem cells under pathological conditions 
where genetic and epigenetic changes induce cellular reprogramming of somatic stem 
cells, producing CSCs as a result (Figure 9). It is well established that CSCs are 
involved in acquisition of drug resistance, metastasis and disease relapse. CSC 
populations can support long-term tumor growth due to their self-renewal capacity, 
telomerase activity and upregulation of multidrug resistance pathways106,107. Currently, 
many investigations aim at identifying and eliminating cancer initiating cells or CSCs, 
selectively, in order to overcome drug resistance and tumor relapse. 
To investigate the dedifferentiation of cancer cells and the generation of CSCs, 
different protocols for the generation of iPSCs, in vitro and in vivo, have been 
implemented for several types of cancer cells108. However, the molecular mechanisms 
that participate during this process are not fully understood. Dedifferentiating cancer 
cells by ectopically expressing the reprogramming transcription factors such as OSKM, 
have been reported in melanoma12,109, Leukemia110, gastrointestinal cancer111, 
osteosarcoma112, colorectal cancer111, and pancreatic ductal adenocarcinoma113.  
As a consequence of reprogramming, induced pluripotent cancer cells (iPCCs) are less 
tumorigenic and have the potential to differentiate into different type cell108,109 (Figure 
9). One advantages of reprogramming cancer cells is the possibility to produce a 
significant number of CSCs to explore their properties and the molecular mechanisms 
that increase therapy resistance. In addition, iPCCs can be used for pharmacological 
screenings in order to discover new therapeutic targets in CSCs.  
Finally, because reprogramming of cancer cells can mimic the heterogeneity of tumors, 
this model represents a suitable platform to study features of tumor progression and to 
identify key factors that are involved in the development of resistance to cancer 
therapies, which remains one of the main problems during treatment of melanoma and 
other types of cancer.  
 45 
 
 
 
Figure 9. Generation of CSC and reprogramming of cancer cells. Genetics and epigenetic 
changes induce somatic stem cells to differentiate into transformed cells. These cells can go 
under reprogramming until CSC and support tumor growth, drug resistance and metastasis. 
Additionally, differentiated cancer cells can be reprogrammed into induced pluripotent cancer 
cells (iPCCs), which can also differentiate into a different cell type.  Adapted from Xiong et al 
2019 Trends in Cell Biology, Bernhardt et al 2017 Stem Cell Reports, and Câmara et al 2016 
Journal of Cancer105,108,109. 
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2. Aims of the thesis 
 
The main aim of this work was to investigate the phenotypic and genetic changes that 
occur during melanoma progression, using partial reprogramming of melanoma cells 
as a model for de-differentiation and resistance to MAPK inhibitors. Additionally, 
identify new suitable candidate molecules that can be used as targets in order to 
overcome resistance to MAPK inhibitors. 
 
The specifics aim of this thesis are: 
 
2.1. Partially reprogram murine melanoma cells using an in vitro model to study 
phenotype switching in melanoma by inducing de-differentiation. 
 
2.2 Evaluate the effect of BRAF and MEK inhibitors on partially reprogrammed 
melanoma cells in order to study therapy resistance. 
 
2.3 Analyze the characteristics of MAPKi-resistant cells to find new candidates that can 
be targeted in order to eliminate or sensitize MAPKi-resistant melanoma cells. 
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3. Materials and Methods 
 
3.1 Materials 
3.1.1 Reagents and Kits 
 
Product Company Catalog No. 
Agarose NEEO Ultra Qualität  Carl Roth 2267.4 
Alamar Blue® Invitrogen DAL1100 
Ampicillin Carl Roth HP62.1 
Ammonium Persulfate (APS) Carl Roth 9592 
BioCoat™ Tumor Cell Invasion 
Systems 
Corning 354165 
BSA-Powder, Albumin Fraction 
V 
Carl Roth 8076.2 
Complete Mini Protease 
Inhibitor Cocktail 
Roche Diagnostics 4693159001 
DH5α Competent Cells Thermo Fisher Scientific 18265017 
Endofree Plasmid Maxi Kit Qiagen 12362 
FITC-Annexin V apoptosis Kit  BD Biosciences 556547 
High Performance 
Chemiluminescence Film 
GE healthcare 28906836 
MouseRef-8 v2.0 Expression 
BeadChips 
Illumina BD-202-0202 
GeneChip® Mouse Genome 
430 2.0 Array 
Affymetrix 900595 
Immobilon PVDF membrane, 
0.45μM 
Merck Millipore IPVH00010 
Luminata Forte Western HRP 
Substrate 
Merck Millipore WBLUF0500 
MicroAmp Optical 96well Plate 
qPCR 
Thermo Fisher Scientific N8010560 
NuPAGETM NovexTM 3-8% Tris-
Acetate Protein Gels 
Thermo Fisher Scientific EA03752BOX  
NuPAGE™ LDS Sample Buffer 
(4X) 
Thermo Fisher Scientific NP0008 
NuPAGE™ Reducing Agent 
(10X) 
Thermo Fisher Scientific NP0004 
PageRuler Plus Prestained 
Protein Ladder 
Life Technologies 26619 
Paraformaldehyde Sigma Aldrich P6148-1KG 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 23225 
Qiaprep Spin Miniprep Kit Qiagen 27106 
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RevertAid First strand cDNA 
Synthesis Kit 
Thermo Fisher Scientific K1622 
Rnase-Free Dnase Set Qiagen 79254 
RNeasy Plus Mini Kit Qiagen 74136 
Skim milk powder Gerbu Biotechnik 16021000 
SYBR Green PCR Master Mix Applied Biosystems 4309155 
TEMED Carl Roth 2367,3 
TritonX-100 Carl Roth 3051,4 
Tween® 20 Applichem A13890500 
Venor Gem Classic Myco PCR 
Kit 
Minerva Biolabs 11-1100 
X-treme GENE® 9 DNA 
Transfection Reagent 
Roche Diagnostics 6365787001 
 
3.1.2 Reagents for cell culture 
 
Product Company Catalog No. 
2-Mercaptoethanol  Gibco®Life 
Technologies 
31350010 
Blasticidin Sigma Aldrich 15205 
Calcein AM Fluorescent Dye Corning 354217 
DMSO  Carl Roth A994.2 
Doxycycline Sigma-Aldrich D1822 
Dulbecco's Modified Eagle's Medium 
(DMEM) 
Thermo Fisher 
Scientific 
10569010 
Embryonic Stem Cells Serum (ES-FCS) Thermo Fisher 
Scientific 
16141079 
Fetal Calf Serum (FCS) Biochrom S0115 
L-Glutamine Thermo Fisher 
Scientific 
25030081 
Knockout™DMEM Thermo Fisher 
Scientific 
10829018 
Murine LIF Sigma-Aldrich L5158 
Non-essential amino acids Sigma-Aldrich M7145 
PBS Sigma-Aldrich D8537 
Penicillin/Streptomycin Sigma-Aldrich P4333 
Polybrene Infection / Transfection 
Reagent 
Sigma Aldrich TR-1003-G 
Puromycin Carl Roth 240,1 
Trypan blue solution Sigma-Aldrich 93595 
Trypsin -EDTA solution Sigma-Aldrich  T3924 
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3.1.3 Human cell lines 
 
Cell Line  Source Cell type Mutation 
A375 ATCC Melanoma cell line BRAF V600E 
HT144 ATCC Melanoma cell line BRAF V600E 
SK-MEL-28 ATCC Melanoma cell line BRAF V600E 
HEK293T ATCC embryonic kidney 
cells 
WT 
4434 Obtained from Dr. Richard 
Marais (University of 
Manchester, UK) 
Melanoma cells BRAF V600E 
C790 Obtained from Dr. Richard 
Marais (University of 
Manchester, UK) 
Melanoma cells NRAS 
 
3.1.4 Antibodies 
 
Specificity Source Company Catalog No. 
Anti-rabbit IgG, HRP-linked Goat Cell signaling 7074S 
Anti-mouse IgG, HRP-linked  Horse Cell signaling 7076 
T-type Ca++ Cav3.2 mouse Santa Cruz sc-377510 
Caspase 3 Rabbit Cell signaling 9662 
ERK Rabbit Cell signaling 4695 
GAPDH  Rabbit Cell signaling CST2118 
SOX2 Rabbit Cell signaling 23064S 
pERK (T202/Y204) Mouse Cell signaling 9106S 
 
3.1.5 Inhibitors 
 
Product Company Catalog No. 
Lomerizine Sigma-Aldrich L6295 
Mibefradil Sigma-Aldrich M5441 
Trametinib (GSK1120212) Selleckchem S2673 
Vemurafenib (PLX4032)  Selleckchem S1267 
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3.1.6 Plasmids 
 
Name Source 
CAV3.2 shRNA 1 TRCN0000044212 
CAV3.2 shRNA 2 TRCN0000044210 
pCMV-dR8.91 (Packaging) Konrad Hochedlinger (Harvard, Boston, USA) 
pCMV-VSV-G (Packaging) Addgene #8454 
pLU-EF1aL-rtTA3-iCherry Wistar Institute 
pLKO.1- puro scrambled  
 
Addgene # 1864 
 
 
3.1.7 Primers 
 
 Mouse qPCR primers  
Amplification target Forward Sequence Reverse Sequence 
Gapdh AGGTCGGTGTGAACGGAT
TTG  
TGTAGACCATGTAGTTGAGG
TCA 
Sox2 TTAACGCAAAAACCGTGAT
G 
GAAGCGCCTAACGTACCACT 
Oct4 endogenous AGTTGGCGTGGAGACTTT
GC 
CAGGGCTTTCATGTCCTGG 
Ssea1 ACGGATAAGGCGCTGGTA
CTA 
GGAAGCCATAGGGCACGAA 
Mitf CCAACAGCCCTATGGCTA
TGC 
CTGGGCACTCACTCTCTGC 
Pmel CCTTGGGCAGGCTCCCTT
GC 
TCCACTGAGGAGCGGGCTG
T 
Cacna1h CGGCCCTACTACGCA ATCCTCGCTGCATTC 
CD271 TGCCGATGCTCCTATGGC
TA 
CTGGGCACTCTTCACACACT
G 
 Human qPCR primers  
18S GAGGATGAGGTGGAACGT
GT 
TCTTCAGTCGCTCCAGGTCT 
SOX2 GCCGAGTGGAAACTTTTG
TCG 
GGCAGCGTGTACTTATCCTT
CT 
ID1 CTGCTCTACGACATG GAAGGTCCCTGATGT 
ID3 GCTTGCTGGACGACA GCGCTGTAGGATTTC 
CAV3.1 GCTCCGGCACAAGTA C CACAATGAGCAGGAA 
CAV3.2 TCGAGGAGGACTTCC TGCATCCAGGAATGG 
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3.1.8 Solutions and Buffers 
 
Transfer buffer (pH 8.3)  
25mM Glycine  
190mM Tris 
20% SDS  
20% Methanol  
dH2O  
Running buffer (pH8.3) 
25mM Glycine  
190mM Tris 
0.1% SDS  
dH2O  
 
TBS 10X (pH 7.6)  
150mM NaCl  
50mM Tris  
dH2O 
Washing buffer (TBST) 
0.02% Tween® 20 
1X TBS 
Blocking buffer (milk) 
5% Skim milk powder 
1x TBS 
Blocking buffer (BSA) 
5% BSA  
1x TBS 
RIPA buffer 
4M NaCl  
1% IGEPAL (Sigma-Aldrich) 
10% Sodium deoxycholate  
10% SDS 
1M Tris, pH 8  
dH2O 
 
TEB buffer 
0.5% Triton X 100 
2mM phenylmethylsulfonyl fluoride  
 0.02% Sodium Azide  
dH2O 
 
SOC Outgrowth Medium  
New England BioLabs (B9020S) 
LB Medium  
20g LB-Medium (Carl Roth, X964.2) 
1l H2O 
Cell freezing medium 
80% FCS 
20% DMSO 
 
Cell freezing medium for reprogramming 
80% ECS 
20% DMSO 
 
Crystal violet solution  
0.5% Crystal violet  
20% Methanol 
dH2O 
HPMC solution 
20%HPMC  
1% Tween 20 
dH2O 
 
3.1.9 Equipment  
 
Product Company 
12 Well Multiwell Plates Grenier Bio-One 
2100 Bioanalyzer Instrument Agilent 
6 Well Multiwell Plates Grenier Bio-One 
AB 7500 Real-Time PCR Machine Applied Biosytems 
CELLSTAR® Cell Culture Flasks Grenier Bio-One 
ChemiDoc™ Touch Imaging System  Bio-Rad 
Culture-inserts 2 well Ibidi 
FACSCanto II BD Biosciences 
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Haemocytometry Neubauer 
Leica DM LS light microscope Leica 
MicroAmp Optical 96well Plate qPCR Thermo Fisher Scientific 
Microplates 24-well Falcon 
Microplates 96-well Falcon 
Nanodrop Spectophotometer ND-1000 Peqlab Biotechnologie GmbH 
Nikon Eclipse Ti Fluorescence Microscope Nikon 
Nunc™ Cell Culture Cryogenic Tubes Thermo Fisher Scientific 
Rotilabo®-syringe filters, 0,22 µm Carl Roth 
Rotilabo®-syringe filters, 0,45 µm Carl Roth 
Tecan Infinite F200 PRO Tecan 
Veriti™ 96-Well Thermal Cycler Thermo Fisher Scientific 
 
3.1.10 Software tools 
 
Software name Source 
7500 Software v2.0.5 Applied Biosystems 
Chipster  Chipster Open source 
FlowJo 7.2.2 FlowJo License 
GraphPad PRISM 8 GraphPad License 
iControl 1.10  TECAN 
Image J NIH  
Image Lab 6.0.1 Bio-Rad 
Ingenuity® Pathway Analysis (IPA®) QIAGEN Bioinformatics 
NIS-Element  Nikon 
Primer-BLAST https://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
TScratch  CSElab 
Software R 3.5 https://www.r-project.org/ 
 
 
3.2 Methods 
3.2.1 Cell Culture  
All cells were maintained under optimal conditions in 5 % CO2 atmosphere and 37°C. 
Human melanoma cell lines A375, HT144, and SK-mel-28 were obtained from ATCC 
(Virginia, USA) and mouse melanoma cells C790 (Nras mutant) and 4434 (BrafV600E 
mutant) were kindly provided by Professor Richard Marais (University of Manchester, 
UK). All cells were cultured in DMEM medium (Thermo Fisher Scientific) supplemented 
with 10 % FCS, 1 % nonessential amino acids, 0.75 % 2-mercaptoethanol, 100 
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units/mL penicillin and 100 µg/mL streptomycin. Cell culture stocks were stored in 
liquid nitrogen at low passages. All cell lines were tested and free of mycoplasma 
contamination.  
Reprogramming experiments were performed using KnockOut™ DMEM medium 
(Thermo Fisher Scientific), supplemented with 10 % ES-FCS (Thermo Fisher 
Scientific), 1 % glutamine, 1 % penicillin/streptomycin, 1 % nonessential amino acids, 
and 100 U/ mL mouse Leukemia Inhibitory Factor.  
 
3.2.2 Partial reprogramming  
The partial reprogramming model was established using mouse melanoma cells C790 
and 4434, based on a previous method describe by Knappe et al 201612. Briefly, cells 
were transduced with a doxycycline-inducible polycistronic lentiviral vector encoding 
for Oct4, Sox2, Klf4 and a blasticidin resistance gene, in combination with a lentiviral 
vector pLU-EF1aL-rtTA3-iCherry (The Wistar Institute) encoding for the constitutively 
active reversed tetracycline-controller trans activator (rtTA) coupled to mCherry. After 
transduction cells were maintained in reprogramming medium containing doxycycline 
(1 μg/ mL) in order to induce transgene expression. At day three, cells were selected 
with Blasticidin (10 μg/mL) and maintained in culture for twenty days.  
 
3.2.3 Lentiviral vector production 
Production of lentiviral vector was performed using human HEK293T cells. HEK293T 
were cultured in DMEM medium (Thermo Fisher Scientific) supplemented with 10 % 
FCS, 1 % nonessential amino acids, 0.75 % 2-mercaptoethanol, 100 units/mL penicillin 
and 100 µg/mL streptomycin. Briefly, 11 μg of each construct of interest is mixed with 
8.25 µg of pCMV-dR8.91 and 5.5 µg of pCMV-VSV-G, lentiviral packaging constructs, 
along with 50 µl of X-tremeGENE™ 9 DNA transfection reagent (Roche Diagnostics). 
After 30 minutes incubation, the mixture was added on HEK293T cells (70 % confluent) 
and cells were incubated in 5 % CO2 atmosphere and 37°C in a biosafety level II 
laboratory S2. After 12 hours, cell medium was discarded and fresh medium was 
added. Subsequently, supernatant was collected at defined time points (24, 36 and 48 
hours). All supernatants were filtered using Rotilabo®-syringe filters, 0,45 µm (Carl 
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Roth) and used for cell transduction immediately or ultracentrifuged and stored at -
80°C.  
For the cell transduction, target cells were harvested 2 days before in 6-well plates at 
low density. On day 1, cells were infected with filtered virus in fresh medium (1:2), 
along with 2 μg/mL polybrene (Sigma-Aldrich) to increase the transduction efficiency 
(optional). After 24 hours, cells were re-infected (filtered virus and fresh medium,1:2). 
On day 4, cells were washed twice with PBS and fresh medium was added. Cells were 
incubated in 5 % CO2 atmosphere and 37°C in a biosafety level I laboratory. After 24 
hours, cells were selected during 3 – 5 days using the respective selection antibiotic 
based on the vector used (1-3 μg/mL of puromycin, Carl Roth; or 8-20 μg/mL of 
blasticidin, Sigma-Aldrich). Knockdown of CACNA1H was performed by using the 
method previously described and shRNA against CACNA1H (TRCN0000044212) and 
(TRCN0000044210) (Sigma-Aldrich), while a scramble shRNA vector (Addgene) was 
used as control. 
 
3.2.4 Bacterial transformation  
In order to obtain amplified plasmid DNA of interest, competent E. coli bacteria were 
transformed. Briefly, competent bacterial cells (DH5α, Sigma-Aldrich) from E. coli were 
thawed on ice, mixed with approximately 100 ng of plasmid DNA and incubated for 40 
min. Next, bacteria suffered heat-shock for 3 min at 42 °C followed by 1 min cool down 
on ice. Next, SOC medium was added to the bacteria-DNA mixture, followed by 1h 
incubation at 37°C and constant shaking. Finally, bacteria were plated on agar plates 
containing the antibiotic ampicillin (100 μg/mL) for selection. After incubation overnight 
at 37°C, growing colonies on agar plates were picked and allowed to grow in LB 
medium containing ampicillin, overnight under constant agitation. Afterwards, plasmid 
was isolated using Qiaprep Spin Miniprep Kit (Qiagen) and analyzed with restriction 
digestion in order to confirm that the plasmid was correct. Then, bacteria carrying the 
correct plasmid were cultured in 200 mL of LB medium containing ampicillin, overnight 
at 37°C and under constant agitation. Finally, Endofree Plasmid Maxi Kit (Qiagen) was 
used to isolate the plasmid of interest, following the instructions of the manufacturer. 
DNA plasmid concentration was determinate using Nanodrop ND-1000 and DNA 
plasmid sequence was confirmed by DNA sequencing (LGC Genomics).  
 
 55 
3.2.5 Inhibitors 
The following inhibitors were used: trametinib (GSK1120212) (Selleckchem), 
vemurafenib (PLX4032) (Selleckchem), lomerizine dihydrichloride (Sigma-Aldrich), 
and mibefradil dihydrochloride hydrates (Sigma-Aldrich). All drugs were dissolved in 
DMSO to desired final concentration, aliquoted and stored according to the 
manufacturers’ guidelines.  
 
3.2.6 RNA Isolation 
Total RNA was isolated using RNeasy Mini Kit (Qiagen) and DNase I digestion for 15 
minutes at RT to remove genomic DNA. Protocol was performed according to the 
manufacturers’ guidelines. RNA concentration and quality were evaluated by 
spectrophotometry using NanoDrop ND1000 device. RNA was used immediately or 
stored at -80°C. 
 
3.2.7 cDNA synthesis 
cDNA was synthesized using cDNA Reverse Transcription kit (Thermo Fisher 
Scientific) according to the manufacturers’ guidelines. First, RNA was dilute with 1 μL 
of Oligo- (dT)18 primer and dH2O up to 12 μL, for a final concentration of 500 ng/μL. 
This mixture was centrifuged and incubate at 65°C for 5 minutes, chilled on ice and 
spun down. Master mix was prepared using 4 μL of 5X Binding Buffer, 1 μL of RiboLock 
RNase inhibitor (20 U/ μL), 2 μL of 10mM dNTP mix and 1 μL of RevertAid M MuL-V-
RT enzyme (200 U/ μL). Afterwards, 8 μL of master mix was added to each reaction 
tube and tubes were incubate for 60 minutes at 42°C, followed by 5 minutes at 70°C.  
cDNA was used immediately or stored at -20°C. 
 
3.2.8 Quantitative real-time PCR 
Quantitative RT-PCR was performed using Applied Biosystems 7500 Real-Time PCR 
Systems (Applied Biosystems) and SYBR Green PCR master mix (Thermo Fisher 
Scientific), according to the manufacturers’ guidelines. All reactions were performed at 
least in triplicates and the amplification signal from the target gene was normalized to 
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GAPDH for mouse samples or 18S for human samples. PCR conditions were: 50°C 2 
minutes, 95°C 10 minutes, 40× cycles of 95 °C 15 seconds, 60°C 1 minute and 72°C 
7 seconds. Primer sequences are listed in the section 3.1.7. 
 
3.2.9 Protein isolation  
Cells were harvested and washed twice with PBS, cell pellets were collected and 
stored at -80°C before protein extraction. Protein isolation was performed using RIPA 
buffer in presence of phosphatase inhibitors. Briefly, cell pellets were disrupted with 
RIPA buffer, mixed and chilled on ice. Protein lysates were centrifuged for at least 30 
minutes at 4°C. Supernatants were collected and quantified.  
Protein quantification was performed using Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific). First, samples were diluted in buffer (1:10) and standards were 
prepared based on manufacturers’ guidelines. Then, 25 μL of sample or standard were 
mixed with 200 μL of BCA reagent in 96-well plates and incubated for 30 minutes at 
37°C. Finally, after incubation, absorbance was obtained using a reader plate (TECAN) 
and protein concentration was calculated based on standard curve.  
 
3.2.10 Western Blot 
Protein samples (20-30 µg) were run on SDS-PAGE gels (at 100V for 2 hours) and 
transferred into PVDF membranes (at 90V for 1 hour). Once transfer was completed, 
membranes were blocked using 5% skim milk or 5% BSA in TBS buffer (1X) for at least 
30 minutes at RT. After blockage, membranes were probed first with the primary 
antibody overnight at 4°C followed by an incubation with the respective secondary 
antibody (1:10000) for 1 hour at RT. Luminata Forte Western HRP Substrate and 
chemiluminescence films were used for detection. The complete list of antibodies used 
can be found in the section 3.1.4. All antibodies were diluted and maintained according 
to manufacturers’ guidelines. 
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3.2.11 Cell viability assay 
Cells were harvested and seeded in 96-well plates in triplicates, at a density of 1×103 
- 1×105 cells. After 24 hours, treatments were added using a range of concentrations 
between 0,0001 µM and 10 µM for 24, 48 or 72 hours. Cell viability was determined 
using Alamar Blue solution (Invitrogen), according to manufacturers’ guidelines. 
Briefly, 10 % of Alamar Blue solution was added to 96-well plates and incubated for 4 
hours at 37°C. Afterwards, fluorescence was measured at 590 nm using a microplate 
reader (Tecan). Cell viability and IC50 values were calculated. 
 
3.2.12 EdU incorporation assay 
Cell proliferation and cell cycle were determined using Click-iT EdU Cell Proliferation 
Kit according to the manufacturer's instructions (Invitrogen). Cells were seeded in 6-
well plates at low density. After 24 hours, EdU compound (10 μM) was added to the 
medium for 2 hours. Cells were harvested, washed and fixed for 15 minutes at RT in 
the dark. After fixation cells were washed again and stained with Click-iT™ Plus 
reaction cocktail containing Alexa Fluor™ 647, for 30 minutes in the dark. Finally, cells 
were treated with Ribonuclease A, stained with PI (50 μg/mL) and analyzed by flow 
cytometry. Data were analyzed using the FlowJo Software. 
 
3.2.13 Apoptosis assay  
Detection of apoptosis was performed using FITC Annexin V Apoptosis Detection Kit I 
(RUO) (DB Biosciences). Cells were seeded at a concentration of 1 x 105 cells/mL in 
6-well plates. Treatments were added to the medium the following day, concentration 
used was calculated based on IC50 values. After 24, 48 or 72 hours, supernatants 
were collected, cells were washed twice with PBS and resuspended in 1X Binding 
Buffer to final concentration of 1 x 106 cells/mL. Later, cell suspension (100 µL) was 
stained with 5 µl of FITC Annexin V and 5 µL of PI. Cells were incubated for 15 minutes 
at RT in the dark. Then, 400 µL of 1X Binding Buffer was added to each tube and then 
analyzed by flow cytometry. Doxorubicin (0.003 µM) was used as a positive control to 
induce apoptosis for 72 hours. Data were analyzed using the FlowJo Software. 
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3.2.14 Invasion assay 
To assess invasion, BioCoat™ Tumor Invasion 24-Multiwell Plates containing 
FluoroBlokTM PET membrane (Corning) were used. First, plates were rehydrated for 2 
hours at 37°C. Then, 500 μL of cell suspension (3×104 cells/mL) was added to the 
apical chambers and 750 μL of chemoattractant (10% FCS in DMEM) to basal 
chambers. Plate was incubated for 22 hours at 37°C and 5 % CO2. After incubation, 
calcein solution (4 µg/mL) was added to a second 24-well plate and incubated for 1hour 
at 37°C and 5 % CO2. Finally, calcein solution was removed and fluorescence was 
read for invading cells at 517 nm, using a microplate reader (Tecan). Data were 
expressed as relative fluorescent units (RFU) of invaded cells.  
 
3.2.15 Migration assay 
Migration assay was performed using Culture-Insert 2 Well in µ-Dish 35 mm (Ibidi). 
Briefly, cell suspension (3×105 cells/mL) was prepared as usual. Inserts were placed 
into the plates and 70 μL of cell suspension was added into each well of the insert. The 
plate was incubated for 24 hours at 37°C, 5% CO2. After incubation, inserts were 
removed and 500 μL of fresh medium was added. Progress of migration was checked 
with a microscope every 12 hours starting from time 0 until 48 hours or when the gap 
was completely closed. Microscope pictures were analyzed using TScratch software. 
Data were expressed as percentage of migration.  
 
3.2.16 Clonogenic assay 
Colony formation assay was performed following the method described by Franken 
and coworkers 114. First, cells were harvested, counted and seeded in 6-well plates 
(1:500) for 24 hours. After cells were attached, treatments were added accordingly with 
the IC50 values, for another 24 hours. Treatments were withdrawn and fresh medium 
was added to cells every 3 - 5 days. After 10 -15 days, colonies were fixed and stained 
with crystal violet solution (0.5%). Colony area was calculated using ImageJ software.  
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3.2.17 In vivo experiments  
In vivo experiments were assessed using NSG xenograft mouse model. Four to six-
week-old female mice were injected subcutaneously (SC) with 100 μL PBS containing 
1 x 106 A375 cells or 5 x 106 HT144 cells, both after 24 hours treatment with 
vemurafenib. Tumor-bearing mice (100-300 mm3) were randomly distributed to four 
groups (n= 40) and treated in one of the following ways: 1) mibefradil (0.25 mg/mL) in 
drinking water for 5 days; 2) vemurafenib (100 mg/kg) dissolved in HPMC solution 
(0.5%) by oral gavage once a day for 5 days; 3) sequential treatment: vemurafenib by 
oral gavage once a day for 5 days and mibefradil in drinking water on the next 5 days; 
and 4) vehicle: 0.5 % HPMC solution by oral gavage once a day for 5 days. Animals 
were treated in 2 cycles. Tumor volume, animal weight (18-20 Kg) and welfare were 
monitored daily. Tumor measurements were conducted using a caliper and tumor 
volume was calculated using the following formula = (length x width2) x 0.5. Animals 
were sacrificed by cervical dislocation once the tumor volume reached 1000 mm3. Drug 
administration or euthanasia did not require the use of anesthesia. Animals were 
maintained in the animal house facility under optimal conditions and with food and 
water ad libitum. All animal experiments were performed according to procedures 
approved by the German authorities.  
 
3.2.18 Whole Genome microarray analysis 
Total RNA was isolated as it is described in section 3.2.5. Afterwards, RNA was labeled 
and hybridized to GeneChip® Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, 
CA, USA) by DKFZ Genomics and Proteomics Core Facility. After normalization using 
RMA method, fold change and p value of differentially expressed genes between + dox 
vs - dox cells were derived from the CEL files, using Chipster software. Additional 
samples were hybridized to Illumina MouseRef-8 v2.0 Expression BeadChips by DKFZ 
Genomics and Proteomics Core Facility. Enrichment analyses were made using 
Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, CA, 
USA, www.ingenuity.com) in order to identify upstream pathways, regulators and 
predictors. The RNA sequencing data can be downloaded with the GEO 
accession number: GSE122399, GSE122402 and GSE122763. 
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Additionally, RNA-Seq data for 459 melanoma patients with follow-up information was 
downloaded from the TCGA-SKCM project 
(https://portal.gdc.cancer.gov/projects/TCGA-SKCM), including 357 metastatic 
samples and 102 primary tumor samples. Recursive partitioning115 based on tissue 
type and log2-transformed FPKM expression values for CACNA1H was performed by 
Dr. Thomas Hielscher from DKFZ biostatistics division, to identify risk groups for overall 
survival. P-value was adjusted for multiple testing using Bonferroni correction. 
Software R 3.5 including add-on packages TCGAbiolinks116 and partykit were used for 
analysis.  
   
3.2.19 Statistical analysis 
All results are expressed as mean ± SEM from at least three or more independent 
experiments. Differences were analyzed using one-way ANOVA followed by post-hoc 
test Bonferroni or Tukey. Data analyses and graphs were made with GraphPad Prism 
(GraphPad Software, Inc.). P < 0.05 was considered statistically significant. Dr. 
Thomas Hielscher from DKFZ biostatistics division used Log-rank test to compare 
survival curves from in vivo experiments. Tumor growth curves were compared 
between treatments by fitting a linear mixed model for tumor volume with predictor 
time, treatment and interaction between time and treatment as fixed effects, and 
random intercept and slope effect for each mouse. The interaction term was tested to 
compare the growth rate relative to the vehicle group. P-values were adjusted for 
multiple comparisons using Holm correction. Software R 3.5 was used for analysis. 
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4. Results 
 
4.1 Partial reprogramming of melanoma cells and induction of de-differentiation.  
 
In order to transform melanoma cells into a more dedifferentiated stage, the method 
described previously by Knappe N et al 2016 was used. Nras-mutant C790 and Braf-
mutant 4434 murine melanoma cells were partially reprogrammed for 20 days using a 
lentiviral vector containing Oct4, Klf4 and Sox2 genes (Figure 10a, b). De-
differentiation status was confirmed by morphological changes observed during the 
process of partial reprogramming (Figure 10c). Additionally, analysis of the expression 
of markers of stemness and melanocytic lineage differentiation showed that Mitf and 
Pmel expression was significantly decreased while endogenous expression of Sox2, 
Oct4 and Ssea-1 increased, confirming that melanoma cells were dedifferentiated 
(Figure 10d). High ectopic expression of transcription factor Oct4 was also confirmed 
in reprogrammed cells (Supplementary Figure S1).  
Moreover, results from RNA array supported the increment in the expression of 
stemness related markers in C790 and 4434 partially reprogrammed murine cells 
(Figure 10e). Enrichment analysis with Ingenuity Pathway Analysis (IPA) predicted 
activation of mouse embryonic stem cell pluripotency-related genes as well as survival-
related pathways (Supplementary Figure S2 and Supplementary Figure S3), 
supporting the successful de-differentiation of the reprogrammed cells.  
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Figure 10. De-differentiation of murine melanoma cells using the partial reprogramming 
in vitro model. a Structure of lentiviral vector used to reprogram cells. Cells were co-infected 
with a lentiviral vector harboring the reverse tetracycline-controlled transactivator (rtTA) and 
an expression vector carrying murine genes for Oct4, Klf4 and Sox2 and a blasticidin-
resistance gene. Cells not induced with doxycycline but transduced with both vectors were 
used as a control. b Schematic representation of the workflow of partial reprogramming 
method. After infection, doxycycline was added to the medium to induce transgene expression 
and on day 3 blasticidin was added to select transduced cells. Cells were reprogrammed for 
20 days. Medium without doxycycline was used for control cells during all experiments. c 
Representative images of morphological changes during partial reprogramming. Scale bars 
represent 10μm. d Real-Time qPCR analysis of the expression of stemness markers Sox2, 
Oct4 and Ssea-1, as well as melanocytic lineage differentiation markers Mitf and Pmel, for 
C790 and 4434 at day 20 of reprogramming. Data was normalized using control cells (“- dox”) 
as reference and GAPDH as housekeeping gene. e Differential Gene Expression analysis. 
Heat map of microarray data showing hierarchical clustering of differentially expressed genes 
between partially reprogrammed C790 (left) or 4434 (right) cells (“+dox”) and control cells (“- 
dox”) at day 20; blue and yellow colors indicate differentially down- or upregulated genes, 
respectively (FC > 2-fold). All data are represented as mean ± SEM of three or more 
independent experiments. Statistical analyses were performed with One Way ANOVA and 
post-hoc test Tukey; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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4.2 Evaluation of melanoma phenotype switching during partial reprogramming.  
 
During melanoma phenotype switching cells can adopt a more invasive and slow-
cycling state39. To determine if the in vitro model of reprogramming previously 
described could simulate features of the melanoma phenotype switching and the 
intermediate stages of tumor progression; proliferation capacity, migration and 
invasion potential of partially reprogrammed cells were evaluated. 
EdU incorporation assay revealed a significant reduction in proliferation of C790 and 
4434 partially reprogrammed cells compared to control cells (“- dox”) (Figure 11a, b) 
by reducing percentage of cells in S phase along with an increase of cells in G1 phase 
at day 20 (Figure 11c). In addition, the reprogrammed cells showed a more aggressive 
phenotype due to the increment in the number of invading cells (Figure 11d, e) and the 
enhanced migration capacity (“+ dox”) compared with the control cells (“- dox”) (Figure 
11f, g). Together, these results suggest that partial reprogramming of murine 
melanoma cells resembles the phenotypic switch that normally occurs during 
melanoma progression.   
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Figure 11. Partially reprogrammed melanoma cells acquire characteristics of cancer 
cells that underwent phenotype switching. a Representative flow cytometry plots showing 
EdU incorporation in C790 and 4434 reprogrammed cells at day 6 and 20. b Percentage of 
EdU positive cells at day 6 and 20 of partial reprogramming is shown. c Quantification of the 
percentage of reprogrammed C790 and 4434 cells in different cell cycle phases at day 6 and 
20 using EdU proliferation assay d Representative fluorescence microscopy images of 
fluorescence microscopy for cell invasion assay in C790 and 4434 reprogrammed cells. e Cell 
invasion assessed by the FluoroBlok invasion assay. Invasion was evaluated at different time 
points during partial reprogramming. After 20 hours incubation, invading cells were labeled and 
relative fluorescence units were obtained (RFUs= relative fluorescence units).  f Scratch assay 
was used to measured migration capacity in C790 and 4434 reprogrammed cells. Percentage 
of migration was calculated after 24, 36 ad or 48 hours. g A representative image of scratch 
assay with C790 and 4434 cells. All data represent the mean ± SEM of three or more 
independent experiments. Statistical analyses were performed with One Way ANOVA and 
post-hoc test Tukey; *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
4.3 Effect of MAPK inhibitor treatment (MAPKi) on the cell viability of partially 
reprogrammed C790 and 4434 cells.  
 
Development of resistance to therapies has been associated with the de-differentiation 
status of tumor cells 117. I evaluated the effect of the treatment with vemurafenib (BRAF 
inhibitor) and trametinib (MEK inhibitor) on the cell viability in C790 and 4434 partially 
reprogrammed cells using the Alamar Blue assay. Cell viability was quantified after 72 
hours of treatment with trametinib, vemurafenib or the combination of trametinib and 
vemurafenib. Cell viability increased in partially reprogrammed cells (“+ dox”) 
throughout day 6, 12 and 20 of reprogramming compared to control cells (“- dox”). 
Treatment with trametinib alone revealed that C790 control cells were more sensitive 
(mean IC50=2.09 ± 0.48 μM) compared to C790 reprogrammed cells at day 20 (mean 
IC50>10 μM) (Figure 12a).  Similarly, single treatment with vemurafenib in 4434 
reprogrammed cells induced an increment in viability in comparison with the control 
cells (Figure 12b).  In addition, combination treatment of vemurafenib and trametinib 
in 4434 reprogrammed cells also revealed a higher IC50 value at day 20 (mean 
IC50=4.38 ± 0.03 μM) compared to 4434 control cells (mean IC50=0.0029 ± 0.0010 
μM) (Figure 12c). This increment in the IC50 values after treatment with MAPKi support 
the development of resistance in dedifferentiated melanoma cells after partial 
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reprograming. All IC50 values for all treatments are shown in Supplementary Tables 
S1 and S2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Effect of partial reprogramming on the sensitivity of C790 and 4434 cells to 
treatment with MAPKi. a Nras-mutant cells (C790) were treated with trametinib (10μM to 
0.0001μM) for 72 hours. Subsequently, an Alamar blue assay was performed and the 
fluorescence emission (read at 590nm) was measured. Cell viability was evaluated at days 6, 
12 and 20 of reprogramming. Cytotoxicity curves represent as the mean ± SEM (n= 6). b, c 
BRAF-mutant cells (4434) were treated with trametinib alone or with the combination of 
trametinib and vemurafenib (10μM to 0.0001μM) for 72 hours, then alamar blue assay was 
performed and the fluorescence emission (read at 590 nm) was measured. Cell viability was 
evaluated at days 6, 12 and 20 of reprogramming. Cytotoxicity curves represent as the 
mean ± SEM (n= 6). Statistical analyses were performed with One Way ANOVA and post-hoc 
test Tukey; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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4.4 Effect of MAPKi treatment on cell death of C790 and 4434 partially 
reprogrammed cells. 
 
In order to investigate whether cell death was also affected in partially reprogrammed 
cells after treatment with MAPKi, apoptosis was measured by flow cytometry using 
Annexin V / PI staining. The percentage of apoptotic cells was significantly reduced 
upon treatment with trametinib (15 μM), at day 6, 12 and 20 in C790 partially 
reprogrammed cells (“+ dox”) compared to control cells (“- dox”). The percentage of 
apoptosis was also diminished in C790 reprogrammed cells after treatment with 
doxorubicin (0.003 μM) (Figure 13a, b). Similar results were obtained at day 12 and 20 
for 4434 reprogrammed cells, treated with trametinib (8 μM), vemurafenib (15 μM) or 
trametinib in combination with vemurafenib (8 μM) (Figure 14a, b). In addition, 
activation of caspase-3 was suppressed in all reprogrammed cells after treatment with 
MAPKi compared to control cells (Figure 13c and Figure 14c). Together these findings 
support that partially reprogrammed cells become less sensitive to MAPKi, due to the 
decrease of caspase activation and apoptosis. 
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Figure 13. Cell death analysis of C790 partially reprogrammed cells after treatment with 
MAPKi. a Representative scatter plots of PI (y-axis) vs. annexin V (x-axis) for day 6 and 20 of 
partial reprogramming of C790 cells. Early apoptotic cells are shown in the lower right quadrant 
and late apoptotic cells are shown in the upper right quadrant. b Apoptosis evaluation after 
staining with FITC-Annexin V/PI. Cells were treated with trametinib (15 μM) and with 
doxorubicin (0.003 μM) to induce apoptosis (positive control) during 72 hours. Percentage of 
apoptotic cells (early and late apoptosis) is shown as mean ± SEM (n=3). c Western Blot 
analysis. Whole cell lysate was immunoblotted with GAPDH and caspase-3 antibodies at day 
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20 of reprogramming after treatment with trametinib (15 μM). Statistical analyses were 
performed with One Way ANOVA and post-hoc test Tukey; ***p < 0.001.  
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Figure 14. Cell death analysis of 4434 partially reprogrammed cells after treatment with 
MAPKi. a Representative scatter plots of PI (y-axis) vs. annexin V (x-axis) for day 6 and 20 of 
partial reprogramming of 4434 cells. Early apoptotic cells are shown in the lower right quadrant 
and late apoptotic cells are shown in the upper right quadrant. b Apoptosis evaluation after 
staining with FITC-Annexin V/PI. Cells were treated with trametinib, vemurafenib (8 μM) and 
with doxorubicin (0.003 μM) to induce apoptosis (positive control during 72 hours. Percentage 
of apoptotic cells (early and late apoptosis) is shown as mean ± SEM (n=3). c Western Blot 
analysis. Whole cell lysate was immunoblotted with GAPDH and caspase-3 antibodies at day 
20 of reprogramming after treatment with trametinib and vemurafenib (8 μM). Statistical 
analyses were performed with One Way ANOVA and post-hoc test Tukey; *p < 0.05, **p < 0.01 
and ***p < 0.001.  
 
4.5 The mechanism behind resistance to MAPKi treatment in C790 and 4434 
partially reprogrammed cells.  
 
Vemurafenib and trametinib are compounds that can specifically target and inhibit 
components of the RAS-RAF-MEK-ERK cascade also known as the MAPK pathway48. 
In order to elucidate the mechanism driving the desensitization of partially 
reprogrammed cells to vemurafenib or trametinib, inhibition of ERK protein from the 
MAPK pathway was analyzed by western blot (Figure 15a, b). Phosphorylation of ERK 
protein was impaired in both C790 and 4434 reprogrammed cells as well as in control 
cells, indicating that the MAPK pathway inhibition is still functional independently from 
the de-differentiation status of the cells.   
To broaden the search for possible resistance mechanisms in C790 partially 
reprogrammed cells after treatment with MAPKi, gene expression analysis was 
performed (Figure 15c). The obtained dendrogram showed some of the genes 
differentially expressed between reprogrammed (“+ dox”) and control cells (“- dox”) 
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after treatment with either DMSO or trametinib. Further analysis using IPA software 
revealed upstream regulators that might be involved in regulation of drug sensitivity 
after partial reprograming of melanoma cells (Figure 15d).  
T-type calcium channels were found to be significantly upregulated in resistant cells, 
suggesting them as a target to be involved in therapy resistance of melanoma. The 
expression of the T-type calcium channel CACNA1H was confirmed on the RNA level 
in both C790 and 4434 partially reprogrammed cells (Figure 15e), highlighting the 
possible connection of calcium signaling with development of resistance to MAPKi. 
The relevance of targeting T-type calcium channels to improve therapy effects in 
melanoma patients was addressed using the TCGA-SKCM database. TCGA analysis 
showed that melanoma patients with high expression of CACNA1H have a worse 
survival outcome compared with those with low CACNA1H expression (p = 0.029) 
(Figure 15f).  Based on these data, the role of T-type calcium channels in the resistance 
to MAPKi of dedifferentiated melanoma cells was further explored. 
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Figure 15. Expression analysis of MAPKi-resistant cells shows an upregulation of T-
Type calcium channels. a, b Western blot analysis. Whole cell lysates from C790 and 4434 
melanoma cells were immunoblotted with antibodies against GAPDH, ERK and P-ERK. c 
Differential gene expression analysis comparing C790 partially reprogrammed cells with 
control cells. Heat map of microarray data showing hierarchical clustering of 2700 differentially 
expressed genes in C790 partially reprogrammed cells after 72 hours treatment with DMSO 
(control) and trametinib; control (“-dox”) and reprogrammed cells (“+dox”) were evaluated both 
at day 20. Blue or yellow colors indicate differentially down- or upregulated genes, respectively 
(FC > 2-fold). d Analysis of gene expression data by a Venn diagram showing the analysis of 
treatments between control cells and reprogrammed cells (2700 genes). The blue circle (474 
genes) indicates the number of genes exclusively expressed in control vs. trametinib (“-dox”); 
yellow circle (1,406 genes) indicates the number of genes exclusively expressed in control vs. 
trametinib (“+dox”). Some of the deregulated genes are listed; green and red colors indicate 
differentially up- or down regulated genes, respectively. Moreover, results from the IPA 
analysis of upstream regulators from C790 partially reprogrammed cells at day 20 after 
treatment with trametinib are listed. e Real-Time qPCR analysis of Cacna1h expression at 
different days of reprogramming for both C790 and 4434 cells. Data were normalized using 
control cells as reference and Gapdh was used as a housekeeping gene. f. Kaplan–Meier 
curves showing the OS of 357 metastatic melanoma patients depending on the level of 
CACNA1H expression. The data were obtained from the TCGA database. Expression values 
for CACNA1H gene were dichotomized into high (red) and low (black) expression using 
recursive partitioning (p = 0.02). Data represent the mean ± SEM of three or more independent 
experiments. Statistical analyses were performed with One Way ANOVA and post-hoc test; 
**p < 0.01 and ***p < 0.001. 
 
4.6 The effect of T type calcium channel inhibition on drug sensitivity of 
reprogrammed and MAPKi-resistant murine melanoma cells.  
 
Reprogrammed cells C790 and 4434 were treated with the calcium channel inhibitors 
mibefradil or lomerizine for 24 hours to determine whether the inhibition of T-type 
calcium channels can induce cell death or affect cell viability. My data showed a 
reduction of cell viability in partially reprogrammed cells (“+ dox”) compared to control 
cells (“- dox”) (Figure 16a and Figure 17a). Dedifferentiated cells at day 20 were slightly 
more sensitive to mibefradil (C790 mean IC50= 5.9 ± 0.74 μM; 4434 mean IC50= 8.87 
± 0.25 μM) than control cells (C790 mean IC50= 6.44 ± 0.66 μM; 4434 mean IC50= 
7.82 ± 0.96 μM). Similar results were observed with lomerizine (Supplementary Tables 
S3 and S4).  
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In addition, single treatments with mibefradil or lomerizine significantly increased the 
percentage of apoptotic cells after 24 hours in both C790 (Figure 16b, c) and 4434 
partially reprogrammed cells (Figure 17b, c), suggesting that inhibition of T-type 
calcium channels promoted apoptosis and affected cell viability in dedifferentiated and 
MAPKi-resistant cells.  
Based on the previous results and the high expression of T-type calcium channel in 
dedifferentiated cells (Figure 15e), the possibility of using these channels as targets to 
re-sensitize MAPKi-resistant cells was considered. Therefore, C790 and 4434 
reprogrammed cells were treated with mibefradil or lomerizine for 24 hours followed by 
treatment with MAPKi for another 24 hours (sequential treatment) to evaluate their 
effect on drug sensitivity.  
The percentage of apoptotic cells was significantly increased in partially reprogrammed 
cells after the sequential treatment (Figure 16b, d and Figure 17b, d). Moreover, the 
capacity of colony formation was significantly reduced in C790 partially reprogrammed 
cells after sequential treatment, (Figure 16e, f), suggesting that previous sensitization 
with mibefradil increased cell death and decreased the capacity of unlimited cell 
reproduction after treatment with MAPKi. Similar results were obtained in 4434 partially 
reprogrammed cells (Figure 17e, f).  
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Figure 16. Inhibition of calcium channels increased sensitivity to MAPK inhibitors in 
C790 partially reprogrammed cells. a Cell viability was performed using alamar blue assay. 
Partially reprogrammed cells C790 were treated with mibefradil (1.25 - 10 μM) for 24 hours. 
After alamar blue assay, the fluorescence (at 590 nm) was measured. Cell viability was 
evaluated at days 6, 12 and 20 of reprogramming. b Representative scatter plots of PI (y-axis) 
vs. annexin V (x-axis) for day 20 of partial reprogramming. Early apoptotic cells are shown in 
the lower right quadrant and late apoptotic cells are shown in the upper right quadrant. Mibe: 
mibefradil (7 μM). Lome: lomerizine (7 μM). Mibe (Lome) >>Tra: sequential treatment with 
mibefradil (lomerizine) for 24 hours, followed by trametinib (15 μM) for another 24 hours. c 
Apoptosis analysis using annexinV/PI staining. Cells were treated with mibefradil (7 μM) and 
lomerizine (7 μM) for 24 hours. Percentage of apoptotic cells (early and late apoptosis) is 
shown as mean ± SEM (n= 3). d. Apoptosis analysis using sequential treatment with calcium 
channel blockers and MAPKi. Percentage of apoptotic cells (early and late apoptosis) is shown 
as mean ± SEM (n= 3). e Clonogenic assay of partially reprogrammed cells C790 treated with 
DMSO (0.01%), mibefradil (7 μM), lomerizine (7 μM), Mibe (Lome) >>Tra: sequential treatment 
with mibefradil (lomerizine), and trametinib (15 μM) for 24 hours. Representative images of 
wells stained with crystal violet are shown. f Percentage of colony area for all treatments is 
shown as mean ± SEM (n=5) for partially reprogrammed cells C790. All data represent the 
mean ± SEM of three or more independent experiments. Statistical analyses were performed 
with One Way ANOVA and post-hoc test; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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Figure 17. Inhibition of calcium channels increases sensitivity to MAPK inhibitors in 
4434 partially reprogrammed cells. a Cell viability was performed using alamar blue assay. 
Partially reprogrammed cells 4434 were treated with mibefradil (1.25 – 10 μM) for 24 hours. 
After alamar blue assay, the fluorescence (at 590 nm) was measured. Cell viability was 
evaluated at days 6, 12 and 20 of reprogramming. b Representative scatter plots of PI (y-axis) 
vs. annexin V (x-axis) for day 20 of partial reprogramming. Early apoptotic cells are shown in 
the lower right quadrant and late apoptotic cells are shown in the upper right quadrant. Mibe: 
mibefradil (7 μM). Lome: lomerizine (7 μM). Mibe (Lome) >> Vem+Tra: sequential treatment 
with mibefradil (lomerizine) 24 hours, followed by vemurafenib + trametinib (8 μM) for another 
24 hours. c Apoptosis analysis using annexinV/PI staining. Cells were treated with mibefradil 
(7 μM) and lomerizine (7 μM) for 24 hours. Percentage of apoptotic cells (early and late 
apoptosis) is shown as mean ± SEM (n= 3). d. Apoptosis analysis using sequential treatment 
with calcium channel blockers and MAPKi. Percentage of apoptotic cells (early and late 
apoptosis) is shown as mean ± SEM (n= 3). e Clonogenic assay of partially reprogrammed 
cells 4434 treated with DMSO (0.01%), mibefradil (7 μM), lomerizine (7 μM), Mibe (Lome) 
>>Vem+Tra: sequential treatment with mibefradil (lomerizine), and Vem+Tra (8 μM) for 24 
hours. Representative images of wells stained with crystal violet are shown. f Percentage of 
colony area for all treatments is shown as mean ± SEM (n= 5) for partially reprogrammed cells 
4434. All data represent the mean ± SEM of three or more independent experiments. Statistical 
analyses were performed with One Way ANOVA and post-hoc test; *p < 0.05, **p < 0.01 and 
***p < 0.001. 
 
4.7 Influence of T-type calcium channel inhibition on the differentiation status of 
reprogrammed and MAPKi-resistant murine melanoma cells.  
  
Although it is well-known that calcium participates as a second messenger in a variety 
of cellular processes, it remains unclear how calcium can regulate self-renewal 
capacity and stemness. It is possible that T-type calcium channels can affect the 
pluripotency status of reprogrammed cells by inducing differentiation. To test this 
hypothesis, the expression of specific stemness-related markers was evaluated in 
C790 and 4434 partially reprogrammed cells after treatment with mibefradil and 
lomerizine.  
The expression of the stemness markers Sox2, Ssea-1 and CD271 was significantly 
reduced in reprogrammed cells after single treatment with mibefradil and lomerizine in 
reprogrammed cells (“+ dox”) compared to control cells (“- dox”) (Figure 18a, b), 
indicating that they adopted a more differentiated phenotype. Together, these and 
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previous data suggest that the modulation of calcium influx improved responses to 
MAPKi-resistant cells by promoting cell death and differentiation. 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Inhibition of T-type calcium channels induced differentiation of 
reprogrammed and MAPKi-resistant melanoma cells. a Real-Time qPCR analysis of the 
expression of the stem cell markers Sox2, Ssea-1 and CD271, at day 20 of partial 
reprogramming of C790 cells, after treatment with mibefradil or lomerizine. Data was 
normalized using control cells as reference and Gapdh as housekeeping gene. b Real-Time 
qPCR analysis of the expression of the stem cell markers Sox2, Ssea-1 and CD271, at day 20 
of partial reprogramming of 4434 cells, after treatment with mibefradil or lomerizine. Data were 
normalized using control cells as reference and Gapdh as housekeeping gene. All data 
represent the mean ± SEM of three independent experiments. Statistical analyses were 
performed with One Way ANOVA and post-hoc test; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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4.8 Expression of T-type calcium channels in human adaptive BRAFi-resistant 
melanoma cells. 
 
Adaptive BRAFi-resistance was induced in human A375, SK-MEL-28 and HT144 
melanoma cells by treating them for 24 hours with vemurafenib (3 µM). Firstly, mRNA 
expression of T-type calcium channels was evaluated in all human cell lines. The data 
showed that expression of Cav3.1 and Cav3.2 genes was enhanced in human 
resistant cells compared to the parental cells (Figure 19a, b, c).  
 
 
 
 
 
 
 
 
 
 
Figure 19. Evaluation of mRNA expression of T-type calcium channels in human 
adaptive BRAFi-resistant melanoma cells. a,b,c Gene expression analysis of Cav3.1 and 
Cav3.2 in human melanoma cell lines A375, SK-MEL-28 and HT144 upon 24 hours treatment 
with vemurafenib (3μM) (adaptive resistance). Data were normalized using control cells as 
reference and 18S as housekeeping gene. All data represent the mean ± SEM of three 
independent experiments. Statistical analyses were performed with One Way ANOVA and 
post-hoc test; *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
4.9 Effect of T-type calcium channel inhibition on cell death in human adaptive 
BRAFi- resistant melanoma cells. 
 
To determine whether the increment in the expression of calcium channels was 
associated with a more dedifferentiated and resistant phenotype, in a similar way to 
reprogrammed murine cells, I tested the effect of mibefradil on cell viability, cell death 
and colony formation ability in human adaptive BRAFi-resistant cells.  
After single treatment for 24 hours with mibefradil, the cell viability of adaptive BRAFi-
resistant cells was reduced (A375 mean IC50= 7.43 ± 0.80 μM; SK-MEL-28 mean 
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IC50= 6.5 ± 0.30 μM; HT144 mean IC50= 2.65 ± 0.14 μM) compared to parental cells 
(A375 mean IC50= 9.63 ± 0.35 μM; SK-MEL-28 mean IC50= 8.17 ± 0.40 μM; HT144 
mean IC50= 5.5 ± 0.41 μM) (Figure 20a and Supplementary Table S5). Single 
treatment with lomerizine did not have a significant effect on the cell viability of A375 
or SK-MEL-28 cells (Supplementary Figure S4a).   
Evaluation of my data showed that single treatment with mibefradil did not affect 
apoptosis in the parental cells but increased apoptosis in all BRAFi-resistant cells 
(“Vem24h >> Mibe24h”). More importantly, mibefradil increased sensitivity to 
vemurafenib when used in sequential manner (“Vem24h >> Mibe24h >> Vem24h”) 
(Figure 11b and Supplementary Figure S4b). These results support the use of calcium 
channel antagonist to re-sensitize resistant cells to BRAFi. 
In addition to these findings, colony formation capacity was impaired in A375 and SK-
MEL-28 BRAFi-resistant cells after treatment with mibefradil (“Vem24h >> Mibe24h”) 
in comparison to single treatment with vemurafenib or DMSO but, the capacity of 
colony formation was completely suppressed in all BRAFi-resistant cells after 
sequential treatment (“Vem24h >> Mibe24h >> Vem24h”) (Figure 20c, d). These 
results are consistent with observations obtained on partially reprogrammed murine 
cells and suggest the possibility of using calcium channels blockers to increase drug 
sensitivity to MAPK inhibitors in resistant cells. 
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Figure 20. Mibefradil increases sensitivity of human adaptive BRAF-resistant melanoma 
cells to MAPK inhibitors. a Human melanoma cells were treated with mibefradil and 
lomerizine (10,9,7,5,2.5 and 1.25 μM) for 24 hours (only mibefradil treatment is shown). After 
alamar blue assay, the fluorescence (590 nm) was measured. b Apoptosis analysis of human 
melanoma, cells were treated with vemurafenib (3 μM) for 24 hours, followed by mibefradil (7 
μM) for 24 hours; after this period cells were re-treated with vemurafenib (3μM) for another 24 
hours (“Vem 24h >> Mibe 24h >> Vem 24h”). Cells were stained and analyzed by flow 
cytometry. Percentage of apoptotic cells (early and late apoptosis) is shown as mean ± SEM 
(n= 5). c Clonogenic assay with human cells A375, SK-MEL-28 and HT144 cells treated for 24 
hours with DMSO (0.01%), mibefradil (7 μM), vemurafenib (3 μM) and sequential treatment 
(Vem 24h >> Mibe 24h >> Vem 24h). Representative images of wells stained with crystal violet 
are shown. d Percentage of colony area for all treatments is shown as mean ± SEM (n= 3) in 
all human melanoma cell lines. All data represent the mean ± SEM of three or more 
independent experiments. Statistical analyses were performed with One Way ANOVA and 
post-hoc test; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.  
 
4.10 Effect of T-type calcium channel inhibition on differentiation status in 
human adaptive BRAFi-resistant melanoma cells.  
 
In order to establish a connection between the blockage of calcium influx and the 
differentiation status of resistant cells, expression of differentiation markers associated 
with adaptive resistance in melanoma, such as ID1, ID3118 and SOX275, were 
evaluated.  
In agreement with earlier results obtained in murine reprogrammed cells, treatment 
with mibefradil significantly reduced the expression of differentiation markers related 
to adaptive resistance, in both parental and resistant cells (Figure 21a, b, c). Even after 
sequential treatment (“Vem24h >> Mibe24h >> Vem24h”), expression of SOX2 was 
suppressed in resistant SK-MEL-28 and HT144 cells on the mRNA (Figure 21a, b) and 
protein level (Figure 21d), supporting a potential role of calcium signaling in stemness 
maintenance.  
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Figure 21. Mibefradil induces differentiation in human adaptive BRAF-resistant 
melanoma cells. a,b,c qPCR analysis of the expression of markers of adaptive resistance 
SOX2, ID1 and ID3 in HT144, SK-MEL-28a and A375 cells respectively, after treatment with 
mibefradil alone or sequential treatment with vemurafenib and mibefradil 
(“Vem24h>>Mibe24h>>Vem24h”). Data were normalized using control cells as reference and 
18S as housekeeping gene. d Western Blot analysis. Whole cell lysates from HT144, SK-MEL-
28 and A375 cells were immunoblotted with antibodies against GAPDH and SOX2. All data 
represent the mean ± SEM of three or more independent experiments. Statistical analyses 
were performed with One Way ANOVA and post-hoc test; *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001.  
 
4.11 Silencing of Cav3.2 and cell death in human adaptive BRAFi-resistant 
melanoma cells.  
 
T-type calcium channel Cav3.2 was silenced in human melanoma cells A375, SK-
MEL-28 and HT144 to test whether it is responsible for the increment in apoptosis and 
sensitization in human adaptive resistant cells. Once verification by qPCR (Figure 22a) 
and western Blot (Figure 22b) of Cav3.2 knockdown in the human cell lines was 
performed, the effect on cell death and differentiation after treatment with vemurafenib 
or with the combination of vemurafenib and trametinib was evaluated.  
Cav3.2 knockdown increased apoptosis in A375 and SK-MEL-28 knockdown cell lines 
compared to the scramble control (Figure 22c and Supplementary Figure S5), thereby 
confirming that induction of apoptosis in BRAFi-adaptive resistant cells was driven by 
inhibition of Cav3.2 calcium channel. Due to limited efficiency of the Cav3.2 knockdown 
(Figure 22a, b), HT144 cells showed a lower percentage of apoptotic cells compared 
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to scramble control. Moreover, colony formation capacity was impaired in Cav3.2 
knockdown cells lines A375 and SK-MEL-28 after treatment with vemurafenib (Figure 
22d, e), supporting that Cav3.2 calcium channel knockdown increased sensitivity of 
resistant cells to BRAFi. These results support the conclusion that the T-type calcium 
channel Cav3.2 plays a role in resistance and survival of melanoma cells.  
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Figure 22. Knockdown of the calcium channel Cav3.2 induces cell death of human 
melanoma cells. a Human melanoma cells A375, SK-MEL-28 and HT144 were transfected 
with sh-Cav3.2 or sh-control (Scramble). After 48 hours selection with puromycin (0.8 μg/mL), 
cells were collected and analyzed by qPCR and western Blot. Analysis of Cav3.2 gene 
expression confirmed the silencing of the gene in all cell lines. b Western blot analysis. Protein 
lysates of human melanoma cells were immunoblotted with antibodies against GAPDH and 
Cav3.2. c Apoptosis assay with A375, SK-MEL-28 and HT144 cells. After treatment with sh-
Cav3.2, cells were stained with annexinV/PI to analyze apoptosis by flow cytometry. 
Percentage of apoptotic cells (early and late apoptosis) is shown as mean ± SEM (n=3). d 
Clonogenic assay with human cells A375 and SK-MEL-28 transfected with sh-Cav3.2 or sh-
control (Scramble), treated for 24 hours with DMSO (0.01%) and vemurafenib (3 μM). 
Representative images of wells stained with crystal violet are shown. e Percentage of colony 
area for all treatments is shown as mean ± SEM (n=3) in A375 and SK-MEL-28 cell lines. All 
data represent the mean ± SEM of three or more independent experiments. Statistical analyses 
were performed with One Way ANOVA and post-hoc test; *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001.  
 
4.12 The effect of knockdown of Cav3.2 on the differentiation status of human 
adaptive BRAFi-resistant melanoma cells.  
 
To determine if the knockdown of Cav3.2 was involved in the observed changes of the 
differentiation status of human melanoma cells, SOX2 expression was evaluated. The 
mRNA (Figure 23a) and protein level (Figure 23b) were substantially reduced in A375 
and SK-MEL-28 knockdown cell lines, indicating a decreased in the stemness 
phenotype. There was no significant difference in SOX2 expression in HT144 Cav3.2 
d e 
A375 
SK-MEL-28 
DMSO Vem DMSO Vem 
Scramble shRNA Cav3.2 
Ve
m
ur
af
en
ib
 (3
𝜇M) 
DM
SO
 (0
.0
1%
) 
Scramble shRNA Cav3.2 
Ve
m
ur
af
en
ib
 (3
𝜇M) 
DM
SO
 (0
.0
1%
) 
A375 
C
ol
on
y 
A
re
a 
 (%
)  
Ve
m
ur
af
en
ib
 (3
𝜇M) 
DM
SO
 (0
.0
1%
) 
Scramble shRNA Cav3.2 
Ve
m
ur
af
en
ib
 (3
𝜇M) 
DM
SO
 (0
.0
1%
) 
C
ol
on
y 
A
re
a 
 (%
)  
SK-MEL-28 
 89 
knockdown cells compared to scramble control most probably due to the low efficiency 
of the Cav3.2 knockdown.  
Considering these data and the previous results, Cav3.2 silencing had a similar effect 
on cell death and differentiation as the pharmacological inhibition of calcium channels 
with mibefradil, confirming the role of T-type calcium channels on drug sensitivity of 
murine and human MAPKi-resistant melanoma cells.  
 
 
 
 
       
 
 
 
 
 
 
 
 
 
Figure 23. Knockdown of the calcium channel Cav3.2 induced differentiation of human 
melanoma cells. a qPCR analysis of SOX2 after silencing Cav3.2 in SK-MEL-28, A375 and 
HT144 human cells. Data were normalized using control cells (scramble) as reference and 
18S as housekeeping gene. e Western Blot analysis. Whole cell lysates of SK-MEL-28, A375 
and HT144 human cells with Cav3.2-knockdown were immunoblotted with antibodies against 
GAPDH and SOX2. All data represent the mean ± SEM of three independent experiments. 
Statistical analyses were performed with One Way ANOVA and post-hoc test; *p < 0.05, 
**p < 0.01, ***p < 0.001 and ****p < 0.0001.  
 
4.13 The effect of mibefradil treatment on tumor growth in vivo and the survival 
of mice injected with human melanoma cells. 
 
A xenograft mouse model was used to evaluate the antitumor effect of the sequential 
treatment (“Vem24h >> Mibe24h >> Vem24h”) in vivo. Mice were inoculated 
subcutaneously with A375 or HT144 cells, which were beforehand treated for 24h with 
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vemurafenib. After the tumor volume reached 100-300 mm3, the animals (n= 40) were 
randomly separated into 4 different treatment groups. Sequential treatment consisted 
of oral administration of vemurafenib for 5 days, follow by mibefradil for another 5 days. 
This workflow was repeated until 2 cycles were completed and finally, vemurafenib 
was applied for the last 5 days of the experiment (Figure 24a, Figure 25a). In parallel, 
single treatments with vemurafenib, mibefradil or vehicle were tested.  
HT144 xenografts showed that single treatments with vemurafenib (p = 0.013) and 
mibefradil (p = 0.025) significantly reduce tumor growth compared to control group 
(vehicle), however, the sequential treatment (p < 0.001) showed the most significant 
and stronger effect on tumor volume compared to control mice (vehicle) (Figure 24b). 
Moreover, survival data showed a better outcome for mice treated with sequential 
treatment compared with control group (p < 0.001) (Figure 24c). Single treatments of 
vemurafenib (p = 0.001) and mibefradil (p < 0.001) showed a significant difference in 
survival compared with vehicle group. These results support the use of mibefradil to 
enhance the antitumor effects of vemurafenib in vivo. 
Regarding A375 xenografts, single treatment with vemurafenib alone led to a slight 
reduction in tumor growth compared to control group (vehicle). In contrast, mice treated 
with mibefradil (p = 0.013) or sequential treatment (p = 0.019) had a significant 
reduction in tumor volume compared to control mice (vehicle) (Figure 25b). 
Considering the survival data, mice treated with sequential treatment showed a better 
outcome, compared with control group (p < 0.001), similar to the effect observed in 
HT144 xenografts (Figure 25c). Single treatments of vemurafenib (p = 0.053) and 
mibefradil (p = 0.063) did not show significant difference in survival compared with 
vehicle group.  
These effects in vivo are consistent with my previous in vitro data on resistant human 
cells and reprogrammed mouse cells, suggesting that the inhibition of T-type calcium 
channels is a promising strategy to sensitize dedifferentiated and resistant melanoma 
cells to MAPKi.  
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Figure 24. Inhibition of tumor growth in vivo and increased survival in HT144 human 
adaptive BRAFi-resistant melanoma xenografts. a Workflow of in vivo evaluation of 
sequential treatment (Vem >> Mibe >> Vem) in adaptive-resistant human cells. HT144 cells 
treated with vemurafenib for 24 hours were injected subcutaneously in female NGS mice. Once 
tumor volume reached 100-300 mm3, animals were randomly divided into 4 groups (n=12), 
and treatments were administered daily as depicted. b Effect of sequential treatment on tumor 
growth in HT144 xenografts, shown as mean and standard deviation of tumor volume over 
time following treatment initiation. Tumor growth curves were compared based on a linear 
mixed model with predictors time, treatment and interaction between time and treatments as 
fixed effects, and random intercept/slope effect. The interaction term was tested to compare 
the growth rate relative to the vehicle group. P-values were adjusted for multiple testing. c 
Kaplan-Meier curves representing survival of HT144 xenografts mice treated with vehicle 
(black line), mibefradil (red line), vemurafenib (green line) and sequential treatment (blue line). 
Survival end point was defined as tumor volume reaching 1000 mm3. The survival curves were 
analyzed with pairwise treatment comparison using log-rank test with adjustment of p-values 
for multiple testing.  
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Figure 25. Inhibition of tumor growth in vivo and increased survival in A375 human 
adaptive BRAFi-resistant melanoma xenografts. a Workflow of in vivo evaluation of 
sequential treatment (Vem >> Mibe >> Vem) in adaptive-resistant human cells. A375 cells 
treated with vemurafenib for 24 hours were injected subcutaneously in female NGS mice. Once 
tumor volume reached 100-300 mm3, animals were randomly divided into 4 groups (n=12), 
and treatments were administered daily as depicted. b Effect of sequential treatment on tumor 
growth in A375 xenografts, shown as mean and standard deviation of tumor volume over time 
following treatment initiation. Tumor growth curves were compared based on a linear mixed 
model with predictors time, treatment and interaction between time and treatments as fixed 
effects, and random intercept/slope effect. The interaction term was tested to compare the 
growth rate relative to the vehicle group. P-values were adjusted for multiple testing. c Kaplan-
Meier curves representing survival of A375 xenografts mice treated with vehicle (black line), 
mibefradil (red line), vemurafenib (green line) and sequential treatment (blue line). Survival 
end point was defined as tumor volume reaching 1000 mm3. The survival curves were analyzed 
with pairwise treatment comparison using log-rank test with adjustment of p-values for multiple 
testing.  
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5. Discussion 
 
Therapy resistance remains an unsolved problem in the treatment of many types of 
cancer. Since melanoma patients have a high risk of developing resistance to current 
treatments, tumor recurrence is still very common5. Understanding the mechanisms 
behind resistance and finding new targets is essential in order to improve treatment 
response and patient survival.  
A dedifferentiated status of cancer cells has been associated with a higher risk of 
acquiring drug resistance117. For this reason, many studies on cancer plasticity and 
cancer stem cells aim at discovering new targets for anticancer drugs that would 
enhance the efficacy of cancer treatments. In vitro reprogramming of cancer cells to a 
less differentiated state mimics the phenotypic and functional changes that occur in 
vivo during cancer progression and that are responsible for the heterogeneity observed 
among cancer cells105. Hence, nuclear reprogramming of cancer cells represents a 
suitable approach to investigate the development of drug resistance in cancer cells.  
In the present work, I used the technique of reprogramming cancer cells to a less 
differentiated state in order to investigate the role of a stem cell-like cancer cell 
population in melanomas that is responsible for the development of resistances to 
BRAF and MEK inhibitors, which are currently used as a standard treatment for 
melanoma patients. Here, it has been demonstrated that partial reprogramming of 
melanoma cells induced a dedifferentiated and aggressive phenotype along with an 
increment in resistance to MAPKi. Moreover, genome expression analysis showed that 
T-type calcium channels were overexpressed in human and murine MAPKi-resistant 
melanoma cells. Inhibition of T-type calcium channels enhanced cell death and 
differentiation in C790 and 4434 murine partially reprogrammed cells as well as in 
human adaptive BRAFi-resistant melanoma cells. Moreover, the efficiency of the 
treatment with the calcium channel blocker, mibefradil, in a sequential manner along 
with vemurafenib was confirmed by the increment in apoptosis and suppression of 
colony formation capacity, which strongly suggest that the use of the calcium channel 
antagonists re-sensitizes resistant melanoma cells to MAPKi. Finally, based on the 
reduction of tumor growth and the increment in overall survival after sequential 
treatment in vivo, it is possible to conclude that T-type calcium channels are potential 
targets to eliminate adaptive resistance of melanoma cells by restoring sensitivity to 
MAPKi.  
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5.1 Melanoma cells adopted a dedifferentiated and aggressive phenotype that is 
highly resistant to MAPK inhibitors upon partial reprogramming. 
 
When differentiated and somatic cells undergo de-differentiation, this is usually 
associated with disease progression and particularly with cancer development. Based 
on this, cellular reprogramming of cancer cells represents a suitable platform to study 
features of tumor progression and to identify factors that contribute to the development 
of resistance to cancer therapies. In vitro de-differentiation or direct reprogramming of 
melanoma cells has been described previously 12,109,119,120. In this work, murine Nras 
and Braf-mutated melanoma cells have been partially reprogrammed to study genetic 
and phenotypic changes that occur during the intermediate stages of melanoma 
progression. A switch in gene expression was observed in C790 and 4434 partially 
reprogrammed cells by increasing the expression of stemness-related genes and 
reducing levels of melanocytic-specific markers, along with a decreased proliferation 
and enhanced invasiveness, which was consistent with the classical features observed 
during phenotype switching in melanoma121,122.  
During development, melanocyte progenitors undergo phenotype switching which is 
necessary for normal melanocyte lineage differentiation. However, the reversion of this 
phenotypic change plays a role in initiating malignant transformation and metastasis121. 
MITF plays a pivotal role during phenotype switching in melanoma and its expression 
level can be used to distinguish between proliferative and invasive melanoma cells. 
Low expression of MITF usually correlates with more invasion, senescence, stem-like 
properties and drug resistance44,123–125, while higher expression leads to an increment 
in proliferation and increased expression of differentiation-related genes that are 
involved in melanin production and melanosome biogenesis125.  
During melanogenesis, additional enzymatic and structural proteins participate in the 
melanosome maturation process, including: tyrosinase (Tyr), tyrosinase-related 
protein 1or 2 (Tyrp1,2), ocular albinism type 1 protein (OA1) and pre-melanosomal 
protein (Pmel). From all the structural proteins, Pmel, a melanocyte-specific type I 
transmembrane glycoprotein, is essential to initiate melanin synthesis and to culminate 
melanosome maturation126. After partial reprogramming of C790 and 4434 murine cells 
for 20 days, cell populations showed a significant reduction in the expression of these 
lineage specific-markers, Mitf and Pmel, together with a higher expression of 
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pluripotency-related genes in mouse (Sox2, Ssea1 and Oct4), indicating a reversion of 
the melanocytic phenotype into a more dedifferentiated stage. 
Considering that cellular de-differentiation has been correlated with development of 
resistance to therapies6,121,127, and that progressive de-differentiation status of 
melanoma cells has been observed in patient samples under standard treatments with 
MAPKi117, I tested the hypothesis that partially reprogrammed cells would be less 
sensitive to BRAF or MEK inhibitors. Consistent with other reports showing that de-
differentiation of human melanoma cells conveyed increased resistance to MAPKi119, 
my results indicate that partially reprogrammed murine melanoma cells had improved 
survival after treatment with trametinib, vemurafenib or with a combination of both 
drugs. 
Although BRAF and MEK inhibitors can efficiently inhibit the MAPK pathway by 
impeding ERK activation, still the most common mechanism of resistance is the 
reactivation of ERK protein48,128. This suggest that tumor cells can rapidly adjust to 
maintain the MAPK cascade active through different mechanisms, assuring an 
elevated cell proliferation and survival. For instance, BRAFi-resistant tumors show 
activation of the MAP3K8 kinase, also known as COT, that can directly activate ERK 
signaling independently of RAF48. 
Moreover, several alternative signaling pathways2,5,74,128 have been implicated either 
in acquired, adaptive or intrinsic resistance in melanoma. The PI3K-mTOR pathway is 
the most frequently activated in resistant tumors, due mainly to deletion of PTEN or 
activation of receptor tyrosine kinases (RTK)129. Additionally, certain genes such as 
MITF, AXL and WNT5A have been associated with development of resistance to 
targeted therapies and melanoma phenotype switching48,130.  
In this study, reactivation of ERK was tested in MAPKi-resistant cells by western blot. 
My data showed that the inhibition of MAPK pathway in partially reprogrammed cells 
altered the phosphorylation status of ERK protein in both C790 and 4434 melanoma 
cells, independently of the dedifferentiated state of the cells. Based on these results 
and the quantity of possible mechanisms responsible of the MAPKi-resistance in 
murine reprogrammed cells, a broader analysis was performed using a gene 
expression array in order to identify new candidate genes that might be involved in the 
development of MAPKi resistance in dedifferentiated cancer cells.  
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5.2. Dedifferentiated and MAPKi-resistant cells overexpressed T-type calcium 
channels.  
 
To identify new candidate genes that might drive possible mechanisms of resistance, 
gene expression analysis of C790 partially reprogrammed cells after treatment with 
trametinib was performed. The obtained data revealed an upregulation of T-type 
calcium channels suggesting a relation between them and de-differentiation and 
resistance. 
T-type calcium channels belong to a big family of voltage gated calcium channels 
(VGCCs). Each subfamily contains several isoforms (Cav1, Cav2 or Cav3) that display 
different electrophysiological properties131. Low voltage-activated and transient 
currents calcium channels are known as T-type channels, which are expressed in 
numerous cell types including non-excitable cells132. Alterations in the expression of 
any of the VGCCs are associated with neurological diseases, such as absence 
seizures133, epilepsies134, neuropathic pain135; or cardiac conditions like 
arrhythmias136. Since T-type calcium channels were reported to be upregulated in 
cancer cells137, growing evidence has shown that VGCCs are widely expressed in 
many types of cancer with a particularly significant increase in the expression of T-type 
calcium channels138–140. This overexpression has been confirmed in 
glioblastoma141,142, ovarian cancer143, breast cancer144, leukemia145 and melanoma146. 
In this study, results confirmed upregulation of T-type calcium channels in MAPKi-
resistant melanoma cells along with an increase in sensitivity of mouse and human 
MAPKi-resistant cells with mibefradil treatment, which led to increased apoptosis and 
a reduction in the capacity of the colony formation capacity of these cells. 
Mibefradil was introduced as a novel calcium channel antagonist for treatment of 
hypertension and angina pectoris in 1997 by Roche Laboratories Inc.147. The 
mechanism of action of mibefradil consists in a selective blockage of transient, low-
voltage-activated T-type calcium channels. Although mibefradil was withdrawn from 
the market in 1998 because of potential risk of interactions with other drugs148, 
currently mibefradil has been repurposed as an anticancer drug and it has been 
already evaluated in clinical trials for glioblastoma treatment.    
Since the role of T-type calcium channels in cancer proliferation was reported by Tau 
Therapeutics LLC149, more studies have indicated that calcium channel blocking 
agents not only affect calcium signaling into the cells but also proliferation and survival 
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of cancer cells. Calcium is a key molecule that participates in many cellular processes, 
including cell proliferation, differentiation and cell cycle control150,151. Targeting T-type 
calcium channels is one strategy to eliminate proliferating cells during the G1-S 
transition in the cell cycle150,152. Previous reports have shown that administration of T-
type calcium channel antagonists (mibefradil or NNC-55-0396) inhibits proliferation 
and induces apoptosis in several cancer cells153, such as U87MG glioma 154,155 , colon 
cancer156, human lung adenocarcinoma (A549), pancreatic cancer (MiaPaCa2) 157, 
melanoma 158 and leukemia cells145. In addition, biopsies from melanoma patients have 
shown a gradual increase in T-type calcium channel expression, which relates to poor 
prognosis159. Based on the analysis, of data from the TCGA, it was possible to correlate 
high expression of the calcium channel subunit CACNA1H with a poor survival 
outcome for melanoma patients compared to patients with low expression of 
CACNA1H.  
In congruence with these previous studies, mibefradil increased apoptosis and 
reduced cell viability and colony formation capacity of both murine MAPKi-resistant 
cells and human adaptive BRAFi-resistant cells. However, this effect was moderated 
and therefore the use of mibefradil was reconsidered as a potentiator of MAPKi effect 
by increasing drug sensitivity of resistant cells. This approach has been proposed for 
brain tumor treatment, and is known as Interlaced Therapy™, which consists in a 
synergistic cancer therapy using mibefradil in a sequential manner with another 
anticancer drug, for instance chemotherapy155. Hence, the potential use of mibefradil 
in a sequential manner with vemurafenib for the treatment of human adaptive BRAFi-
resistant melanoma cells was addressed in the present study.  
 
5.3 In vitro and in vivo inhibition of T-type calcium channels re-sensitized 
resistant melanoma cells to MAPK inhibitors. 
 
In order to assess whether mibefradil is capable of sensitizing resistant melanoma cells 
to MAPK inhibitors, a similar sequential treatment as previously described was tested. 
The sequential treatment Interlaced Therapy™ consists first in the administration of a 
T-type calcium channel antagonist, like mibefradil, to arrest cancer cells at the G1/S 
checkpoint of the cell cycle, then mibefradil is withdrawn and the administration of 
chemotherapy begins. In this way, mibefradil can synchronize the cell cycle of the cells 
and increase the number of cancer cells entering S phase at the same time. As a 
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consequence, the number of sensitive cancer cells increases which makes them more 
vulnerable to the lethal effect of the chemotherapy155.  
This approach has not been described before for treatment of resistant cell populations 
in melanoma, using inhibitors of the MAPK pathway. Therefore, considering the 
overexpression of T-type calcium channels and the effect of mibefradil on MAPKi-
resistant melanoma cells, a sequential treatment using mibefradil and vemurafenib 
was evaluated in this study.  
Inhibition of T-type calcium channels has been used to sensitize other types of resistant 
cancer cells to specific therapies or conventional chemotherapy, in a sequential 
treatment manner. In ovarian cancer, mibefradil enhances antitumor activity of 
carboplatin in vitro and in vivo143,160. In a similar way, in glioblastoma, mibefradil 
treatment enhances the anti-tumor effects of ionizing radiation161, and the combination 
of mibefradil with temozolomide has shown a stronger therapeutic effect and  increased 
patient survival142. Consistent with these findings, my results showed that mibefradil 
potentiates the lethal effect of MAPKi when it is administered sequentially to MAPKi-
resistant cells in vitro and in vivo.  
Sequential treatments with mibefradil and either trametinib, vemurafenib or a 
combination of both, effectively increased cell death and completely suppressed the 
colony formation capacity of resistant murine and human melanoma cells. Moreover, 
in vivo data from mouse xenograft experiments not only showed a significant reduction 
of tumor volume after treatment with mibefradil (single treatment) or with the sequential 
treatment, but also mice treated in a sequential manner showed increased survival 
compared to the control group, while single treatments with mibefradil or vemurafenib 
did not result in significant differences in survival. These results were further supported 
through the silencing of Cav3.2 transcript in BRAFi-adaptive human resistant cells. 
Based on the data obtained with the Cav3.2 knockdown, it is possible to conclude that 
Cav3.2 was played an important role for colony formation and cell viability.  
Taking together, in vitro and in vivo data suggest that the inhibition of T-type calcium 
channels is a promising strategy to enhance the response of resistant melanoma cells 
to MAPKi. 
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5.4 Inhibition of t-type calcium channels induced differentiation in murine 
MAPKi-resistant and dedifferentiated melanoma cells. 
 
The role of T-type calcium channels in de-differentiation and drug resistance remains 
unclear. Zang et al. (2017) showed that T-type calcium channels are enriched in 
glioblastoma stem-like cells, which are resistant to temozolomide. They demonstrated 
that blockade of calcium channels can re-sensitize resistant cells to treatments but also 
induce differentiation142.  
Resistant and dedifferentiated cancer cells display many features that are also found 
in the classical stem cells like self-renewal capacity, and are responsible for generating 
heterogeneous tumor cell population. It has been reported that BRAFi-resistant 
melanoma cells develop a metastatic phenotype along with an upregulation of certain 
cancer stem cells-markers like CD27136,162,163. 
CD271 marker is also known as low-affinity nerve growth factor receptor (LNGFR) and 
belongs to a family of receptors for neurotrophins, proteins that stimulate survival and 
differentiation in neuronal cells. CD271 has been reported to be expressed in many 
different types of cells, from mesenchymal stem cells164 to even tumor initiating cells165. 
Moreover, several reports have shown that knockdown of CD271 induced apoptosis166, 
reduced migration167 and tumorigenicity, and abolished stemness-related features in 
melanoma cells168. These properties qualify CD271 as a suitable factor to establish 
de-differentiation and resistance in melanoma cells.  
Besides CD271, dedifferentiated cells also express other markers, including the stage 
specific embryonic antigens (SSEA): SSEA1, SSEA3 and SSEA4. SSEA1 is a marker 
exclusively expressed on the surface of murine ESCs and is absent in human 
ESCs169,170. Expression of SSEA1 increases upon differentiation of human cells, but 
decreases during differentiation of mouse cells170, therefore, SSEA1 is indeed a proper 
marker to evaluate differentiation status of murine cells.  
To elucidate the effect of the inhibition of T-type calcium channels on the de-
differentiation status of MAPKi-resistant cells, expression levels of stemness-markers 
in murine reprogrammed melanoma cells were evaluated. After single treatment with 
mibefradil or lomerizine, a significant decrease of the stemness-related markers Sox2, 
Ssea1 and CD271 at the mRNA level in C790 and 4434 dedifferentiated cells was 
observed. These results are in line with the reduction of Oct3/4 and Nanog expression 
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in mouse ESCs reported in another study, after pharmacological blockage of T-type 
calcium channels or knockdown with Cav 3.2 siRNA171. 
Although it is well known that calcium can regulate different pathways that are involved 
in differentiation, little is known about the role of calcium in the maintenance of 
pluripotency of dedifferentiated cells. Calcium currents have been detected in G1 to S 
transition during cell cycle progression in diverse cell lines, including dedifferentiated 
cells 172–174, indicating that calcium is also a key regulator during stem cells 
proliferation. In addition, dedifferentiated mouse ESCs have been reported to show 
voltage-dependent Ca+ and/or Na+ currents, which influence cell cycle progression and 
maintenance of self-renewal in murine ESCs171. All these data confirmed that calcium 
blockage affects the de-differentiation status of resistant melanoma cells by reducing 
expression of stemness-related genes, making them more vulnerable to treatment. 
 
5.5 Inhibition of T-type calcium channels induced differentiation of human 
adaptive vemurafenib-resistant melanoma cells. 
 
As mentioned before, resistant cancer cells display a more dedifferentiated phenotype 
that provides them a survival advantage during treatment. In order to find out whether 
inhibition of T-type calcium channels also induces differentiation in adaptive resistant 
cells, an analysis of the expression levels of stemness-related genes in human 
adaptive BRAFi-resistant melanoma cells was performed after inhibition of T-type 
calcium channels. 
Studies on glioblastoma stem-like cells (GSC) have reported differentiation of GSC 
induced upon treatment with mibefradil, which was confirmed by downregulation of 
stemness markers, CD133, nestin, Bmi1 and SOX2142. SOX2 is a well-known 
transcription factor that participates in many processes during mammalian 
development, including: self-renewal maintenance of pluripotency, germ cell 
differentiation, hematopoiesis, and more175. Due to the variety of functions, SOX2 is 
highly involved in many developmental disorders and cancer progression. High 
expression of SOX2 has been connected with a more stem cell-like phenotype in 
cancer cells and with an increase of drug resistance in different tumors75,176.  
Among the types of drug resistance in melanoma, the adaptive resistance to BRAF 
inhibitors involved critical mechanisms at the very early stage of treatment. During 
initial response to treatment, certain cancer cells are able to adapt and tolerate the 
 101 
effects of the anti-cancer drugs, this generates clones with adaptive resistance that 
can survive and proliferate. This type of resistance it develops a few hours after the 
onset of treatment and is driven by different mechanisms.  Factors like SOX275, 
LNGFR74, ID1 and ID3118 are not only highly expressed in melanoma cells with an 
adaptive resistance to targeted therapy, but also their expression correlates with a 
more dedifferentiated phenotype, making them appropriate markers to evaluate de-
differentiation in therapy-resistant melanoma cells.  
Inhibition of T-type calcium channels with mibefradil in human adaptive resistant 
melanoma cells decreased the expression of markers SOX2, ID1 and ID3. Reduction 
of SOX2 expression was also confirmed upon Cav3.2 knockdown in human melanoma 
cells at the mRNA and protein level, supporting the role of Cav3.2 in maintenance of 
the dedifferentiated status. 
Taking together all results, it is possible to conclude that the inhibition of T-type calcium 
channels induces differentiation in human adaptive resistant cells, suggesting that 
calcium signaling might be involved in the maintenance of de-differentiation status and 
in the development of resistance in melanoma.  
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6. Conclusions 
 
The present work has demonstrated that partial reprogramming of melanoma cells in 
vitro provides a suitable platform to study MAPKi-resistance in melanoma and to 
identify new potential targets that can improve current therapies. Using this model, it 
was possible to confirm that treatment with T-type calcium antagonists induced 
differentiation and increase apoptosis in resistant melanoma cells (Figure 26). In 
addition, results corroborated that single treatment with mibefradil was capable of 
eliminating cancer cells. However, applying mibefradil in a sequential treatment 
together with BRAFi was more effective against MAPKi-resistant cells in vitro and in 
vivo, reducing tumor growth and increasing OS of mice.  
Noteworthy, a phase I study has determined the maximum permissible dose of 
mibefradil when given sequentially with temozolomide in patients with recurrent high-
grade gliomas177, supporting the safety and therapeutic use of mibefradil in humans. 
This approach of sequential administration not only enhances the effects of 
conventional anticancer treatments but also reduces exposure time for the patients to 
chemotherapy, reducing their burden.  
The results showed in this work, highlight the possibility of using T-type calcium 
channel antagonists to restore sensitivity to MAPKi and achieve successful melanoma 
tumor remission without relapse.  
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Figure 26. Schematic overview of the main effects on dedifferentiated and MAPKi-
resistant melanoma cells induced by the inhibition of T-type calcium channels. Partial 
reprogramming of melanoma cells induced de-differentiation and increased resistance to 
MAPK inhibitors. Blockage of calcium channels, using mibefradil, could sensitize resistant cells 
to MAPK inhibitors resulting in increased cell death and differentiation.  
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8. Supplemental material 
 
8.1 Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S1. Real-Time qPCR analysis of the exogenous expression of the 
reprogramming factor Oct4 in C790 and 4434 at day 20 of reprogramming. Data were 
normalized using control cells (“- dox”) as reference and GAPDH as a housekeeping gene. 
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Supplementary Figure S2. IPA Analysis for pathways deregulated in C790 
reprogrammed cells at day 20. Genes related to mouse embryonic stem cell pluripotency 
were predicted to be activated (Oct4, Sox2, ID, Frizzled, PI3K and Ras).  
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Supplementary Figure S3. IPA Analysis for canonical pathways activated or inhibited in 
C790 and 4434 reprogrammed cells at day 20. Pathways associated with pluripotency and 
survival were activated in dedifferentiated reprogrammed cells.  
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Supplementary Figure S4. Effect of mibefradil and lomerizine in human adaptive BRAF-
resistant melanoma cells. a Cell viability assay. After 24 hours treatment with vemurafenib, 
cells were treated with lomerizine (1.25 – 10 μM) for 24 hours. b Representative scatter plots 
of PI (y-axis) vs. annexin V (x-axis) for human melanoma cells after single treatment with 
vemurafenib (15 µM), mibefradil (7 µM), and sequential treatment with vemurafenib and 
mibefradil (“Vem24h>>Mibe24h>>Vem24h”). Early apoptotic cells are shown in the lower right 
quadrant and late apoptotic cells are shown in the upper right quadrant. 
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Supplementary Figure S5. Apoptosis analysis after Cav3.2 knockdown in human 
melanoma cells. a,b,c Representative scatter plots of PI (y-axis) vs. annexin V (x-axis) for all 
human Cav3.2 knockdown melanoma cells and scramble control, after single treatment with 
vemurafenib (3 µM) and combination treatment with vemurafenib and trametinib (3 µM). Early 
apoptotic cells are shown in the lower right quadrant and late apoptotic cells are shown in the 
upper right quadrant. 
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8.2 Supplementary Tables 
 
Table S1. IC50 values of trametinib for C790 partially reprogrammed cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. IC50 values of vemurafenib, trametinib and a combination of both drugs for 
4434 partially reprogrammed cells.  
 
4434 (Braf 
V600E) 
IC50 values 
trametinib (µM) vemurafenib  (µM) trametinib + vemurafenib  (µM) 
- doxycycline + doxycycline - doxycycline + doxycycline - doxycycline + doxycycline 
day 6 0.0009 ± 0.0003 0.0008 ± 0.0002 5.40 ± 0.67 1.01 ± 0.05 0.0002 ± 0.0001 0.000007 ± 0.000001 
day 12 0.0026 ± 0.0005 0.24 ± 0.06 4.94 ± 1.06 > 10µM 0.0038 ± 0.0053 0.0008 ± 0.0002 
day 20 0.0025 ± 0.0001 > 10µM 5.05 ± 0.35 > 10µM 0.0029 ± 0.0020 4.38 ± 0.03 
 
 
 
 
 
 
 
 
 
C790 (NRAS 
mutant) 
IC50 values 
trametinib (µM) 
- doxycycline + doxycycline 
day 6 
1.71 ± 0.99 0.20 ± 0.02 
day 12 
2.16 ± 1.42 > 10µM 
day 20 
2.09 ± 0.48 > 10µM 
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Supplementary Table S3. IC50 values of calcium channel inhibitors for C790 cells (Nras 
mutant) during partial reprograming at days 6, 12 and 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S4. IC50 values of calcium channels inhibitors for 4434 cells 
(BrafV600E) during reprograming at day 20. 
 
4434 ( Braf 
V600E) 
IC50 values 
mibefradil  (µM) lomerizine  (µM) 
- doxycycline + doxycycline - doxycycline + doxycycline 
day 20 7.82 ± 0.96 8.87 ± 0.25 > 10µM > 10µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C790 (Nras 
mutant) 
IC50 values 
lomerizine  (µM) mibefradil  (µM) 
- doxycycline + doxycycline - doxycycline + doxycycline 
day 6 10.60 ± 0.01 5.59 ± 0.83 6.16 ± 0.25 3.70 ± 0.28 
day 12 8.49 ± 0.16 7.18 ±0.25 5.75 ± 0.35 5.39 ± 0.01 
day 20 10.02 ± 1.69 7.05 ± 0.49 6.44 ± 0.66 5.09 ± 0.74 
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Supplementary Table S5. IC50 values of vemurafenib and calcium channel inhibitors 
for human melanoma cell lines during adaptive resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Cell line 
IC50 Values 
vemurafenib (µM) mibefradil (µM) lomerizine(µM) 
A375 parental 0.54 ± 0.58 9.63 ± 0.35 > 10 µM 
A375 + Vem 24h > 10 µM 7.43 ± 0.80 > 10 µM 
SK-MEL-28 parental 1.3 ± 0.24 8.17 ± 0.40 > 10 µM 
SK-MEL-28 + Vem 24h > 10 µM 6.5 ± 0.30 > 10 µM 
HT144 parental 0.7 ± 0.24 5.5 ± 0.41 6.24 ± 0.15 
HT144 + Vem 24h > 10 µM 2.65 ± 0.14 3.07 ± 0.14 
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